Securities Purchase Agreement



 EXHIBIT 10.1 
 SECURITIES PURCHASE AGREEMENT 
 SECURITIES PURCHASE AGREEMENT (this “AGREEMENT,” “PURCHASE
AGREEMENT,” or “SECURITIES PURCHASE AGREEMENT”), dated as of March 30, 2007, by and among AVICENA GROUP, INC., a Delaware corporation, (“COMPANY”), and each buyer identified on the signature pages hereto (each,
including its successors and assigns, a “BUYER” and collectively the “BUYERS”). 
 WHEREAS: 
 A. The Company and the Buyers are executing and delivering this Agreement in reliance upon the exemption from securities registration afforded by Rule 506
under Regulation D (“REGULATION D”) as promulgated by the United States Securities and Exchange Commission (the “SEC”) under the Securities Act of 1933, as amended (the “1933 ACT” or the “SECURITIES ACT”);

 B. Buyers desire to purchase and the Company desires to issue and sell in a private offering, upon the terms and conditions set forth in
this Agreement, (i) Series B Preferred Stock (the “PREFERRED STOCK”) of the Company and (ii) Warrants (as defined in Section 1(b)(iv) in the form described in this Agreement, to purchase shares of Common Stock of the Company
in a private offering. The minimum aggregate offering amount of this offering of the Preferred Stock to all of the Buyers shall be Two Million Dollars (U.S. $2,000,000)(the “MINIMUM AMOUNT”) and the maximum aggregate offering amount of
this offering of the Preferred Stock to all of the Buyers shall be Fourteen Million Seven Hundred Fifty Thousand U.S. Dollars (U.S. $14,750,000) (the “MAXIMUM AMOUNT”)(collectively, the “OFFERING”), provided that no more than Ten
Million U.S. Dollars (U.S. $10,000,000) of Preferred Stock may be placed to Buyers who are not Series A Exchange Investors (as defined below); 
 C. The terms of the Preferred Stock, including the terms on which the Preferred Stock may be converted into common stock, $0.001 par value, of the Company (the “COMMON STOCK”), are set forth in Certificate of Designation of Rights
and Preferences of Series B Preferred Stock of Avicena Group, Inc. (the “CERTIFICATE OF DESIGNATION”), in the form attached hereto as Exhibit A; 
 D. Contemporaneous with the execution and delivery of this Agreement, the parties hereto are executing and delivering a Registration Rights Agreement, in the form attached hereto as EXHIBIT B (the
“REGISTRATION RIGHTS AGREEMENT”), pursuant to which the Company has agreed to provide certain registration rights under the 1933 Act and the rules and regulations promulgated thereunder, and applicable state securities laws. 
 NOW THEREFORE, the Company and each Buyer, severally and not jointly, hereby agree as follows: 
  

 1 








 1. PURCHASE AND SALE OF PREFERRED STOCK AND WARRANTS. 
 (a) CERTAIN DEFINITIONS. This Securities Purchase Agreement, the Certificate of Designation, the Registration Rights Agreement, the Warrants, and
any other agreements delivered together with this Agreement or in connection herewith shall be referred to herein as the “TRANSACTION DOCUMENTS.” The Company and each Buyer (severally and not jointly) mutually agree to the terms of each of
the Transaction Documents. For purposes hereof: 
 “APPROVED STOCK PLAN” means any employee benefit plan which has been duly adopted
by a majority of the non-employee members of the Board of Directors of the Company or a majority of the members of a committee of non-employee directors established for such purpose, pursuant to which the Company’s securities may be issued to
any employee, consultant, advisor, officer or director (or any individual who has accepted an offer of employment) for services provided to the Company. 
 “COMMON STOCK EQUIVALENTS” means any securities of the Company or the Subsidiaries which would entitle the holder thereof to acquire, directly or indirectly, at any time Common Stock, including without
limitation, any debt, preferred stock, rights, options, warrants or other instrument that is at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock. 
 “CONVERTIBLE SECURITIES” shall have the meaning ascribed to it in the Certificate of Designation. 
 “EFFECTIVE DATE” shall have the meaning ascribed to it in the Registration Rights Agreement. 
 “ELIGIBLE MARKET” means the over the counter Bulletin Board (“OTC-BB”), the New York Stock Exchange, Inc., the NYSE Arca, the NASDAQ
Capital Market, the NASDAQ Global Market, the NASDAQ Global Select Market or the American Stock Exchange. 
 “EXEMPT ISSUANCE”
means the issuance of (a) any Common Stock issued or issuable upon exercise of any options to employees, officers, directors, consultants and advisors (and any individuals who have accepted an offer of employment), in each case in connection
with any Approved Stock Plan, up to a maximum amount of Common Stock not to exceed the amounts (at the specified prices and times) specified on SCHEDULE 1(A)(and provided that no such options shall be issued to consultants or advisors unless
such options are unregistered and subject to volume limitations under Rule 144), (b) securities upon the exercise, exchange of, conversion or redemption of, or payment of interest or liquidated or similar damages on, any Securities issued
hereunder, (c) other securities exercisable, exchangeable for, convertible into, or redeemable for shares of Common Stock issued and outstanding on the date of this Agreement, provided that such securities have not been amended since the date
of this Agreement to directly or indirectly increase the number of such securities or to decrease the exercise, exchange or conversion price of such securities (and including any issuances of securities pursuant to the anti-dilution provisions of
any such securities), and (d) any Common Stock issued or issuable in connection with any acquisition by the Company, whether through an acquisition of stock or a merger of any business, assets or technologies the primary purpose of which is not
to raise equity capital. 
  

 2 








 “MARKET PRICE,” for any security as of any date, shall have the meaning ascribed to it in the
applicable security. 
 “OPTIONS” shall have the meaning ascribed to it in the Certificate of Designation. 
 “PAYMENT SHARES” shall mean (i) Default Shares (as defined in the Certificate of Designation), (ii) Interest Payment Shares (as
defined in the Certificate of Designation) and (iii) shares issuable upon conversion of Failure Payments and other Required Cash Payments (as each is defined in the Certificate of Designation) into Common Stock of the Company. The Payment
Shares shall be treated as Common Stock issuable upon conversion of the Preferred Stock for all purposes hereof and thereof and shall be subject to all of the limitations and afforded all of the rights of the other shares of Common Stock issuable
hereunder or thereunder, including without limitation, the right to be included in the Registration Statement (as defined in the Registration Rights Agreement) filed pursuant to the Registration Rights Agreement. 
 “PERSON” shall mean an individual, a limited liability company, a partnership, a joint venture, an exempted company, a corporation, a trust, an
unincorporated organization and a government or any department or agency thereof. 
 “REQUIRED HOLDERS” shall have the meaning
ascribed to it in the Certificate of Designation. 
 “SERIES A EXCHANGE INVESTORS” shall mean Buyers who, prior to the date of this
Certificate of Designation, were holders of Series A Preferred Stock, and elect to exchange their Series A Preferred Stock into Series B Preferred Stock. 
 “STATED VALUE” shall have the meaning ascribed to it in the Certificate of Designation. 
 (b)
PURCHASE OF PREFERRED STOCK AND WARRANTS. Subject to the satisfaction or waiver of the terms and conditions of this Agreement, on the Closing Date (as defined below), the Company shall issue and sell to each Buyer and each Buyer, severally and
not jointly, agrees to purchase from the Company the Preferred Stock in a principal amount equal to the Subscription Amount (as defined in Section 10) and an accompanying number of Warrants (as described below) to purchase a number of shares
equal to the Warrant Amount (as defined below). 
 (i) Form of Certificate of Designation. The Certificate of Designation
shall be in the form annexed hereto as EXHIBIT “A.” 
 (ii) Form Of Payment. On or before the Closing Date
(as defined below), (i) each Buyer shall pay the purchase price (the “PURCHASE PRICE”) for the Preferred Stock and the Warrants to be issued and sold to it at the Closing (as defined below) by wire 

  

 3 








 
transfer of immediately available funds to the Company, in accordance with the Company’s written wiring instructions, against delivery of duly executed
certificates representing the Holder’s Preferred Stock (“PREFERRED STOCK CERTIFICATE”) having an aggregate Stated Value equal to the Purchase Price and the number of Warrants equal to the Warrant Amount, and (ii) the Company
shall deliver such Preferred Stock Certificates and Warrants duly executed on behalf of the Company, to such Buyer, against delivery of such Purchase Price. 
 (iii) Closing Date. Subject to the satisfaction or waiver of the terms and conditions of this Agreement, the “Closing” with respect to a Buyer shall occur when subscriber funds representing the
aggregate Stated Value of the Preferred Stock being purchased by the Buyers are transmitted by wire transfer of immediately available funds by each Buyer to the Company, assuming that the Transaction Documents are signed by both parties prior to or
within three (3) business days following such transmission. The date of the Closing shall be referred to herein as the “CLOSING DATE.” Unless otherwise mutually agreed by the parties, the last Closing hereunder shall occur not later
than May 21, 2007. The Closing contemplated by this Agreement shall occur on the applicable Closing Date at the offices of the Company, or at such other location as may be agreed to by the parties. 
 (iv) Warrants. Each Buyer’s Preferred Stock shall be accompanied by a number of warrants (“WARRANTS”) equal to the Stated
Value of the Preferred Stock being purchased by such Buyer, divided by the Initial Conversion Price (as defined in the Certificate of Designation) of the Series B Preferred Stock, multiplied by 50% (the “WARRANT AMOUNT”). The
Warrants shall be in the form of the Warrant annexed hereto as EXHIBIT “D,” except that the “Initial Exercise Price,” as defined therein, shall equal $7.00 (the “INITIAL WARRANT EXERCISE PRICE”), subject
to adjustment therein. The Warrants shall contain Exercise Price adjustment provisions that are consistent with the adjustment provisions afforded to the Conversion Price of the Preferred Stock in the Certificate of Designation and shall have a five
(5) year term. 
 (v) Closing Deliveries. On the Closing Date, the Company will deliver or cause to be delivered to each
Buyer: 
 (A) the items required to be delivered to Buyer pursuant to Section 8, duly executed by the Company where so required,

 (B) certificates representing the applicable Preferred Stock and Warrant, 
 (C) a certificate (“CLOSING CERTIFICATE”) signed by its chief executive officer or chief financial officer (1) representing the truth and
accuracy of all the representations and warranties made by the Company contained in this Agreement, as of the applicable Closing Date, as if such representations and warranties were made and given on all such dates, (2) adopting the covenants
and conditions set forth in this Agreement in relation to the applicable Preferred Stock and Warrants, and (3) certifying that an Event of Default has not occurred, 
  

 4 








 (D) a legal opinion in substantially the form of Exhibit E attached hereto in relation to the
Company, the applicable Preferred Stock, the applicable Warrant and the Transaction Documents (“CLOSING LEGAL OPINION”), 
 (E)
Preferred Stock with an aggregate Stated Value equal to such Buyer’s Subscription Amount, registered in the name of such Buyer, 
 (F)
a Warrant registered in the name of such Buyer to purchase up to a number of shares of Common Stock equal to the Warrant Amount (as defined in Section 1(b)(iv)) with an exercise price equal to the Initial Warrant Exercise Price (as defined in
Section 1(b)(iv)) subject to adjustment therein, 
 (G) Limited Standstill Agreements, in the form of Exhibit F hereto, duly executed
by each of the Designated Insiders (as defined in Section 4(r)); 
 (H) The Company shall have delivered to such Buyer a true copy of
certificate evidencing the formation and good standing of the Company and each of its Subsidiaries in such entity’s jurisdiction of formation issued by the Secretary of State (or comparable office) of such jurisdiction, as of a date within 10
days of the Closing Date. 
 (I) The Company shall have delivered to such Buyer a true copy of certificate evidencing the Company’s
qualification as a foreign corporation and good standing issued by the Secretary of State (or comparable office) of each jurisdiction in which the Company conducts business, as of a date within five (5) days of the Closing Date. 
 (J) The Company shall have delivered to such Buyer a certified copy of the Certificate of Incorporation as certified by the Secretary of State of the
State of Delaware within five (5) days of the Closing Date. 
 On the Closing Date, each Buyer shall deliver or cause to be delivered to
the Company the following: 
 (A) this Securities Purchase Agreement and the Registration Rights Agreement duly executed by such Buyer,

 (B) such Buyer’s Subscription Amount by wire transfer to the account as specified in writing by the Company (subject to offsets for
the Lead Investor’s Fee, as to the Lead Investor, and subject to any expenses to which such Buyer is entitled). 
 2. BUYER’S
REPRESENTATIONS AND WARRANTIES. Each Buyer represents and warrants to the Company solely as to such Buyer that: 
 (a) INVESTMENT
PURPOSE. As of the date hereof, the Buyer is purchasing the Preferred Stock and the shares of Common Stock issuable upon conversion of the Preferred Stock or otherwise pursuant to the Certificate of Designation and the other Transaction
Documents (including, without limitation, the Payment Shares) (such shares of Common Stock 

  

 5 








 
being collectively referred to herein as the “CONVERSION SHARES”) and the Warrants and the shares of Common Stock issuable upon exercise thereof
(the “WARRANT SHARES” and, collectively with the Preferred Stock, Warrants and Conversion Shares, the “SECURITIES”) for its own account and not with a present view towards the public sale or distribution thereof, except pursuant
to sales registered or exempted from registration under the 1933 Act; PROVIDED, HOWEVER, that by making the representations herein, the Buyer does not agree to hold any of the Securities for any minimum or other specific term and reserves the right
to dispose of the Securities at any time in accordance with or pursuant to a registration statement or an exemption under the 1933 Act and applicable state securities laws. 
 (b) ACCREDITED INVESTOR STATUS. The Buyer is an “accredited investor” as that term is defined in Rule 501(a) of Regulation D (an
“ACCREDITED INVESTOR”). 
 (c) RELIANCE ON EXEMPTIONS. The Buyer understands that the Securities are being offered and sold
to it in reliance upon specific exemptions from the registration requirements of United States federal and state securities laws and that the Company is relying upon the truth and accuracy of, and the Buyer’s compliance with, the
representations, warranties, agreements, acknowledgments and understandings of the Buyer set forth herein in order to determine the availability of such exemptions and the eligibility of the Buyer to acquire the Securities. 
 (d) INFORMATION. The Buyer and its advisors, if any, have been furnished with all materials relating to the business, finances and operations of
the Company and materials relating to the offer and sale of the Securities which have been requested by the Buyer or its advisors. The Buyer and its advisors, if any, have been afforded the opportunity to ask questions of the Company. Neither such
inquiries nor any other due diligence investigation conducted by Buyer or any of its advisors or representatives shall modify, amend or affect Buyer’s right to rely on the Company’s representations and warranties contained in
Section 3 below. The Buyer understands that its investment in the Securities involves a significant degree of risk. 
 (e)
GOVERNMENTAL REVIEW. The Buyer understands that no United States federal or state agency or any other government or governmental agency has passed upon or made any recommendation or endorsement of the Securities. 
 (f) TRANSFER OR RE-SALE. The Buyer understands that (i) except as provided in the Registration Rights Agreement, the sale or re-sale of the
Securities has not been and is not being registered under the 1933 Act or any applicable state securities laws, and the Securities may not be transferred or resold unless (a) the Securities are sold pursuant to an effective registration
statement under the 1933 Act, (b) the Buyer shall have delivered to the Company an opinion of counsel (which opinion shall be in form, substance and scope reasonably satisfactory to counsel to the Company) to the effect that the Securities to
be sold or transferred may be sold or transferred pursuant to an exemption from such registration, (c) the Securities are sold or transferred to an “affiliate” (as defined in Rule 144 promulgated under the 1933 Act (or a successor
rule) (“RULE 144”) of the Buyer who agrees to sell or otherwise transfer the Securities only in accordance with this Section 2(f) and who is an Accredited Investor, or (d) the Securities are sold pursuant to Rule 144 or Rule
144(k); and (ii) any sale of such Securities made in 

  

 6 








 
reliance on Rule 144 or Rule 144(k) may be made only in accordance with the terms of said Rule. Notwithstanding the foregoing or anything else contained
herein to the contrary, the Securities may be pledged as collateral in connection with a BONA FIDE margin account or other lending arrangement. 
 (g) ORGANIZATION; AUTHORIZATION; ENFORCEMENT. Buyer is a duly organized, validly existing and in good standing under the laws of the jurisdiction in which it is organized. Buyer has all requisite power and authority to enter into and
perform this Agreement and the Registration Rights Agreement and to consummate the transactions contemplated hereby and thereby in accordance with the terms hereof and thereof. The execution and delivery of this Agreement and the Registration Rights
Agreement have been duly and validly authorized and no further consent or authorization of Buyer, its manager or members is required. This Agreement has been duly executed and delivered on behalf of the Buyer, and this Agreement constitutes, and
upon execution and delivery by the Buyer of the Registration Rights Agreement, such agreement will constitute, legal, valid and binding agreements of the Buyer enforceable in accordance with their terms, except (i) as limited by general
equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application affecting enforcement of creditors’ rights generally, (ii) as limited by applicable laws relating to the
availability of specific performance, injunctive relief or other equitable remedies and (iii) insofar as indemnification and contribution provisions may be limited by applicable law. 
 (h) RESIDENCY. The Buyer’s residency is as indicated on its signature page hereto. 
 (i) KNOWLEDGE AND EXPERIENCE. Buyer has such knowledge and experience in financial and business matters that it is capable of evaluating the
merits and risks of the investment in the Securities. 
 (j) SHORT SALES PRIOR TO THE DATE HEREOF. Buyer and its Affiliates have not
from the time that such Buyer first received a term sheet (written or oral) from the Company or any other person setting forth the material terms of the transactions contemplated hereunder until the date hereof entered into or effected, or attempted
to induce any third party to enter into or effect, any short sales of the Common Stock, or any hedging transaction which establishes a net short position with respect to the Common Stock. 
  

 7 








 (k) NO GENERAL SOLICITATION. Buyer has not been the subject of general solicitation with respect
to this Offering. 
 (l) INDEPENDENT INVESTMENT DECISION. Such Buyer has independently evaluated the merits of its decision to
purchase the Securities pursuant to the Transaction Documents, and such Buyer confirms that it has not relied on the advice of any other Buyer’s business and/or legal counsel in making such decision. 
 (m) LEGAL AUTHORIZATION FOR DIVIDENDS AND REDEMPTIONS. As of the Closing Date, the Company is legally authorized, under applicable law, to
(i) pay the Dividends required under the Certificate of Designation and (ii) pay the price of any Redemption (as defined in the Certificate of Designation). 
 3. REPRESENTATIONS AND WARRANTIES OF THE COMPANY. The Company represents and warrants to each Buyer that, except as set forth on the Company’s disclosure schedules or any update thereto prior to the
Closing Date (so long as such schedules do not contain any material adverse change): 
 (a) ORGANIZATION AND QUALIFICATION. The Company
and each of its Subsidiaries (as defined below), if any, is a corporation duly organized, validly existing and in good standing under the laws of the jurisdiction in which it is incorporated, with full power and authority (corporate and other) to
own, lease, use and operate its properties and to carry on its business as and where now owned, leased, used, operated and conducted. SCHEDULE 3(A) sets forth a list of all of the Subsidiaries of the Company and the jurisdiction in which each is
incorporated. The Company and each of its Subsidiaries is duly qualified as a foreign corporation to do business and is in good standing in every jurisdiction in which its ownership or use of property or the nature of the business conducted by it
makes such qualification necessary except where the failure to be so qualified or in good standing would not have a Material Adverse Effect. “MATERIAL ADVERSE EFFECT” means any material adverse effect on (i) the Securities,
(ii) the business, operations, assets, financial condition or prospects of the Company and its Subsidiaries, if any, taken as a whole, (iii) on the transactions contemplated hereby or by the agreements or instruments to be entered into in
connection herewith or (iv) the authority or the ability of the Company to perform its obligations under this Agreement, the Registration Rights Agreement, the Preferred Stock or the Warrants. “SUBSIDIARIES” means any corporation or
other organization, whether incorporated or unincorporated, in which the Company owns, directly or indirectly, any equity or other ownership interest. 
 (b) AUTHORIZATION; ENFORCEMENT. (i) The Company has all requisite corporate power and authority to enter into and perform this Agreement, the Registration Rights Agreement, the Preferred Stock and the
Warrants and to consummate the transactions contemplated hereby and thereby and to issue the Securities, in accordance with the terms hereof and thereof, (ii) except as otherwise set forth in SCHEDULE 3(B), the execution and delivery of this
Agreement, the Registration Rights Agreement, the Preferred Stock and the Warrants by the Company and the consummation by it of the transactions contemplated hereby and thereby (including without limitation, the issuance of the Preferred Stock and
the Warrants and the issuance and reservation for issuance of the Conversion Shares issuable upon conversion of or 

  

 8 








 
otherwise pursuant to the Preferred Stock and the Warrant Shares issuable upon exercise of or otherwise pursuant to the Warrants) have been duly authorized
by the Company’s Board of Directors and no further consent or authorization of the Company, its Board of Directors, or its stockholders is required, (iii) this Agreement has been duly executed and delivered by the Company, and
(iv) this Agreement constitutes, and upon execution and delivery by the Company of the Registration Rights Agreement, the Preferred Stock and the Warrants, each of such agreements and instruments will constitute, a legal, valid and binding
obligation of the Company enforceable against the Company in accordance with its terms, except (i) as limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general
application affecting enforcement of creditors’ rights generally, (ii) as limited by applicable laws relating to the availability of specific performance, injunctive relief or other equitable remedies and (iii) insofar as
indemnification and contribution provisions may be limited by applicable law. 
 (c) CAPITALIZATION. As of the date hereof, the
authorized capital stock of the Company is as set forth on SCHEDULE 3(C-1). The authorized capital stock of the Company consists of 100,000,000 shares of Common Stock, par value $.001 per share, of which approximately 51,000,000 shares
are outstanding as of the date hereof and 5,000,000 shares of preferred stock, par value $0.001 per share, of which 900,000 shares of Series A Convertible Preferred Stock are outstanding as of the date hereof. There are no outstanding
securities which are convertible into shares of Common Stock, whether such conversion is currently exercisable or exercisable only upon some future date or the occurrence of some event in the future, except as disclosed on SCHEDULE (C-1). If any
such securities are listed on SCHEDULE (C-1), the number or amount of each such outstanding convertible security and the conversion terms are set forth in said SCHEDULE (C-1). All of such outstanding shares of capital stock set forth in SCHEDULE
3(C-1) are, or upon issuance will be, duly authorized, validly issued, fully paid and nonassessable. 
 Except as disclosed in SCHEDULE
3(C-1), no shares of capital stock of the Company are subject to preemptive rights or any other similar rights of the stockholders of the Company or any liens or encumbrances imposed through the actions or failure to act of the Company. Except as
disclosed in SCHEDULE 3(C-2), as of the effective date of this Agreement, (i) there are no outstanding options, warrants, scrip, rights to subscribe for, puts, calls, rights of first refusal, agreements, understandings, claims or other
commitments or rights of any character whatsoever relating to, or securities or rights convertible into or exchangeable for any shares of capital stock of the Company or any of its Subsidiaries, or arrangements by which the Company or any of its
Subsidiaries is or may become bound to issue additional shares of capital stock of the Company or any of its Subsidiaries, (ii) there are no agreements or arrangements under which the Company or any of its Subsidiaries is obligated to register
the sale of any of its or their securities under the 1933 Act (except the Registration Rights Agreement) and (iii) there are no anti-dilution or price adjustment provisions contained in any security issued by the Company (or in any agreement
providing rights to security holders) that will be triggered by the issuance of the Preferred Stock, the Warrants, the Conversion Shares or Warrant Shares. The Company has furnished to each Buyer true and correct copies of the Company’s
Certificate of Incorporation as in effect on the date hereof (“CERTIFICATE OF INCORPORATION”), the Company’s By-laws, as in effect on the date hereof (the “BY-LAWS”), and the terms of all securities convertible into or
exercisable 

  

 9 








 
for Common Stock of the Company and the material rights of the holders thereof in respect thereto. In the event that the date of execution of this Agreement
is not the Closing Date, the Company shall provide each Buyer with a written update of this representation signed by the Company’s President and Chief Executive or Chief Financial Officer on behalf of the Company as of the Closing Date. The
issuance and sale of the Securities will not obligate the Company to issue shares of Common Stock or other securities to any Person (other than the Buyers) and will not result in a right of any holder of Company securities to adjust the exercise,
conversion, exchange or reset price under any of such securities. No further approval or authorization of any stockholder, the Board of Directors of the Company or others is required for the issuance and sale of the Securities. There are no
stockholders agreements, voting agreements or other similar agreements with respect to the Company’s capital stock to which the Company is a party or, to the knowledge of the Company, between or among any of the Company’s stockholders.

 (d) ISSUANCE OF SHARES. Upon issuance upon conversion of the Preferred Stock and upon exercise of the Warrants in accordance with
their respective terms, and receipt of the exercise price therefor, the Conversion Shares and Warrant Shares, along with any Payment Shares or any other shares issued pursuant to the terms of the Transaction Documents, will be validly issued, fully
paid and non-assessable, and free from all taxes, liens, claims and encumbrances and shall not be subject to preemptive rights or other similar rights of stockholders of the Company and will not impose personal liability upon the holder thereof.

 (e) ACKNOWLEDGMENT OF DILUTION. The Company understands and acknowledges the potentially dilutive effect to the Common Stock upon
the issuance of the Conversion Shares upon conversion of or otherwise pursuant to the Certificate of Designation or upon issuance of the Warrant Shares upon exercise of or otherwise pursuant to the Warrants. The Company’s directors and
executive officers have studied and fully understand the nature of the Securities being sold hereunder. The Company further acknowledges that its obligation to issue Conversion Shares upon conversion of or otherwise pursuant to the Certificate of
Designation, to issue Warrant Shares upon exercise of or otherwise pursuant to the Warrants in accordance with this Agreement, and to otherwise issue shares of Common Stock to the Buyer is absolute and unconditional regardless of the dilutive effect
that such issuance may have on the ownership interests of other stockholders of the Company. Taking the foregoing into account, the Company’s Board of Directors has determined, in its good faith business judgment, that the issuance of the
Securities hereunder and under the Certificate of Designation and the Warrants and the consummation of the transactions contemplated hereby and thereby are in the best interest of the Company and its stockholders. 
 (f) NO CONFLICTS. Except as otherwise set forth in SCHEDULE 3(F), the execution, delivery and performance of each of the Transaction Documents by
the Company and the consummation by the Company of the transactions contemplated hereby and thereby (including, without limitation, the issuance and reservation for issuance of the Conversion Shares and Warrant Shares) will not (i) conflict
with or result in a violation of any provision of the Certificate of Incorporation or By-laws, (ii) trigger any resets of conversion or exercise prices in other outstanding convertible securities, warrants or options of the Company,
(iii) trigger the issuance of securities by the Company to any third party, (iv) violate or conflict with, or result in a breach of any provision of, or constitute a default (or an event which with notice or lapse of 

  

 10 








 
time or both would become a default) under, or give to others any rights of termination, amendment, acceleration or cancellation of, any agreement,
indenture, patent, patent license or instrument to which the Company or any of its Subsidiaries is a party, or (v) result in a violation of any law, rule, regulation, order, judgment or decree (including federal and state securities laws and
regulations and regulations of any self-regulatory organizations to which the Company or its securities are subject) applicable to the Company or any of its Subsidiaries or by which any property or asset of the Company or any of its Subsidiaries is
bound or affected (except, in the case of clauses (i), (iv) and (v) above, for such conflicts, defaults, terminations, amendments, accelerations, cancellations and violations as would not, individually or in the aggregate, have a Material
Adverse Effect). Neither the Company nor any of its Subsidiaries is in violation of its Certificate of Incorporation, By-laws or other organizational documents and neither the Company nor any of its Subsidiaries is in default (and no event has
occurred which with notice or lapse of time or both could put the Company or any of its Subsidiaries in default) under, and neither the Company nor any of its Subsidiaries has taken any action or failed to take any action that would give to others
any rights of termination, amendment, acceleration or cancellation of, any agreement, indenture or instrument to which the Company or any of its Subsidiaries is a party or by which any property or assets of the Company or any of its Subsidiaries is
bound or affected, except for possible defaults as would not, individually or in the aggregate, have a Material Adverse Effect. The businesses of the Company and its Subsidiaries, if any, are not being conducted, and shall not be conducted so long
as a Buyer owns any of the Securities, in violation of any law, ordinance or regulation of any governmental entity the violation of which would have a Material Adverse Effect. Except as disclosed in SCHEDULE 3(F) or as specifically contemplated by
this Agreement or as required under the 1933 Act and any applicable state securities laws, the Company is not required to obtain any consent, authorization or order of, or make any filing or registration with, any court, governmental agency,
regulatory agency, self regulatory organization or stock market or any third party in order for it to execute, deliver or perform any of its obligations under this Agreement, the Registration Rights Agreement, the Certificate of Designation or the
Warrants in accordance with the terms hereof or thereof or to issue and sell the Preferred Stock and Warrants in accordance with the terms hereof and to issue the Conversion Shares upon conversion of or otherwise pursuant to the Certificate of
Designation and the Warrant Shares upon exercise of or otherwise pursuant to the Warrants. Except as disclosed in SCHEDULE 3(F), all consents, authorizations, orders, filings and registrations which the Company is required to obtain pursuant to the
preceding sentence have been obtained or effected on or prior to the date hereof. The Company is not in violation of the listing requirements of the Principal Market (as defined herein) and does not reasonably anticipate that the Common Stock will
cease to be listed on the Principal Market in the foreseeable future. The Company and its Subsidiaries are unaware of any facts or circumstances which might give rise to any of the foregoing. 
 (g) SEC DOCUMENTS; FINANCIAL STATEMENTS. Except with respect to filings under Section 16 of the Exchange Act where the Company assists the
filing persons as an accommodation and except as to Form 8-K Current Reports as to those items where the failure to timely file does not, in and of itself, make the Company ineligible to utilize a Form S-3 registration statement, since at least
November 14, 2005 (the “REFERENCE DATE”), the Company has timely filed all reports, schedules, forms, statements and other documents required to be filed by it with the SEC pursuant to the reporting requirements of the Securities
Exchange 

  

 11 








 
Act of 1934, as amended (the “1934 ACT”) (all of the foregoing filed prior to the date hereof and since at least the Reference Date, and all
exhibits included therein and financial statements and schedules thereto and documents (other than exhibits to such documents) incorporated by reference therein, being hereinafter referred to herein as the “SEC DOCUMENTS”). For purposes of
this Agreement, “TIMELY FILED” shall mean that the applicable document was filed (i) by its original due date under the 1934 Act, or, if a request for an extension was timely filed, (ii) by such extended due date. True and
complete copies of the SEC Documents are available on the SEC’s internet website (www.sec.gov), except for such exhibits and incorporated documents. Upon the request of a Buyer, the Company will promptly provide copies of the SEC Documents to
such Buyer. As of their respective dates, the SEC Documents complied in all material respects with the requirements of the 1934 Act and the rules and regulations of the SEC promulgated thereunder applicable to the SEC Documents, and none of the SEC
Documents, at the time they were filed with the SEC, contained any untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements therein, in light of the
circumstances under which they were made, not misleading. None of the statements made in any such SEC Documents is, or has been, required to be amended or updated under applicable law (except for such statements as have been amended or updated in
subsequent filings prior to the date hereof). As of their respective dates, the financial statements of the Company (and the notes thereto) included in the SEC Documents complied as to form in all material respects with applicable accounting
requirements and the published rules and regulations of the SEC with respect thereto. Such financial statements have been prepared in accordance with United States generally accepted accounting principles, consistently applied, during the periods
involved (except (i) as may be otherwise indicated in such financial statements or the notes thereto, or (ii) in the case of unaudited interim statements, to the extent they may not include footnotes or may be condensed or summary
statements) and fairly present in all material respects the consolidated financial position of the Company and its consolidated Subsidiaries as of the dates thereof and the consolidated results of their operations and cash flows for the periods then
ended (subject, in the case of unaudited statements, to normal year-end audit adjustments). Except as set forth in the financial statements of the Company included in the SEC Documents, the Company has no liabilities, contingent or otherwise, other
than (i) liabilities incurred in the ordinary course of business subsequent to the date of the Company’s most recent 10-QSB or 10-KSB and (ii) obligations under contracts and commitments incurred in the ordinary course of business and
not required under generally accepted accounting principles to be reflected in such financial statements, which, individually or in the aggregate, are not material to the financial condition or operating results of the Company. 
 (h) ABSENCE OF CERTAIN CHANGES. Except for losses incurred in the ordinary course of business that have been publicly disclosed at least five
(5) days prior to the date hereof or as set forth on SCHEDULE 3(H) or 3(I)(B) hereof, since the date of the Company’s most recent 10-QSB or 10-KSB, there has been no material adverse change and no material adverse development in the
assets, liabilities, business, properties, operations, financial condition, results of operations or prospects of the Company or any of its Subsidiaries. For purposes of this Section 3(h), the terms “MATERIAL ADVERSE CHANGE” and
“MATERIAL ADVERSE DEVELOPMENT” shall exclude continuing losses that are consistent with the Company’s historical losses. 
  

 12 








 (i) ABSENCE OF LITIGATION. Except as disclosed in SCHEDULE 3(I)(A), to the knowledge of the
Company or any of its Subsidiaries, there is no action, suit, claim, proceeding, inquiry or investigation by any court, public board, government agency, self-regulatory organization or body pending or, to the knowledge of the Company or any of its
Subsidiaries, threatened against or affecting the Company or any of its Subsidiaries, or their officers or directors in their capacity as such. SCHEDULE 3(I)(B) contains a complete list and summary description of any known pending or threatened
proceeding against or affecting the Company or any of its Subsidiaries, without regard to whether it, if adversely decided, would have a Material Adverse Effect. The Company and its Subsidiaries are unaware of any facts or circumstances which might
give rise to any of the foregoing. 
 (j) PATENTS, COPYRIGHTS, ETC. All of the Company’s material patents, patent applications,
Patents (as defined below), patent rights, inventions, know-how, trade secrets, trademarks, trademark applications, service marks, service names, trade names and copyrights (“INTELLECTUAL PROPERTY”) are set forth in SCHEDULE 3(J-1)
hereof. Any liens, encumbrances or licenses that have been granted against the Intellectual Property are listed in SCHEDULE 3(J-2). Except as otherwise set forth on SCHEDULE 3(J-2), the Company owns all right and title to the Intellectual
Property free and clear of any liens or encumbrances and has not granted any licenses or rights to use any of the Patents to any third party. The Company and each of its Subsidiaries owns or possesses the requisite licenses or rights to use all
Intellectual Property necessary to enable it to conduct its business as now operated, including but not limited to the intellectual property set forth in SCHEDULE 3(J-1) hereof (and, except as otherwise set forth in SCHEDULE 3(J-2) hereof, to the
best of the Company’s knowledge, as presently contemplated to be operated in the future), except for such licenses or rights the failure of which to own or possess would not, individually or in the aggregate, have a Material Adverse Effect;
there is no claim or action by any person pertaining to, or proceeding pending, or to the Company’s knowledge threatened, which challenges the right of the Company or of a Subsidiary with respect to any Intellectual Property necessary to enable
it to conduct its business as now operated (and, except as otherwise set forth in SCHEDULE 3(J-2) hereof, to the best of the Company’s knowledge, as presently contemplated to be operated in the future), except for actions or claims which, if
adversely decided, would not have a Material Adverse Effect; to the best of the Company’s knowledge, the Company’s or its Subsidiaries’ current and intended products, services and processes do not infringe on any Intellectual Property
or other rights held by any person, and the Company is unaware of any facts or circumstances which might give rise to any of the foregoing. The Company and each of its Subsidiaries have taken reasonable security measures to protect the secrecy,
confidentiality and value of their Intellectual Property. 
 For purposes hereof, “PATENTS” means all domestic and
foreign letters patent, design patents, utility patents, industrial designs, inventions, trade secrets, ideas, concepts, methods, techniques, processes, proprietary information, technology, know-how, formulae, rights of publicity and other general
intangibles of like nature, now existing or hereafter acquired (including, without limitation, all domestic and foreign letters patent, design patents, utility patents, industrial designs, inventions, trade secrets, ideas, concepts, methods,
techniques, processes, proprietary information, technology, know-how and formulae described in SCHEDULE 3(J-1) hereof), all applications, registrations and recordings thereof (including, without limitation, applications, registrations and
recordings in the United States Patent and 

  

 13 








 
Trademark Office, or in any similar office or agency of the United States or any other country or any political subdivision thereof), and all reissues,
divisions, continuations, continuations in part and extensions or renewals thereof, in each case owned by the Company or an of its Subsidiaries. 
 (k) NO MATERIALLY ADVERSE CONTRACTS, ETC. Except as otherwise set forth on SCHEDULE 3(K), neither the Company nor any of its Subsidiaries is subject to any charter, corporate or other legal restriction, or any judgment,
decree, order, rule or regulation which in the judgment of the Company’s officers has or is reasonably likely in the future to have a Material Adverse Effect. Neither the Company nor any of its Subsidiaries is a party to any contract or
agreement, or has knowledge of a breach of any contract or agreement to which the Company or any of its Subsidiaries is a party, either of which in the judgment of the Company’s officers has or is reasonably likely to have a Material Adverse
Effect. 
 (l) TAX STATUS. Except as set forth on SCHEDULE 3(L), the Company and each of its Subsidiaries has made or filed all
federal, state and foreign income and all other tax returns, reports and declarations required by any jurisdiction to which it is subject (unless and only to the extent that the Company and each of its Subsidiaries has set aside on its books
provisions reasonably adequate for the payment of all unpaid and unreported taxes) and has paid all taxes and other governmental assessments and charges that are material in amount, shown or determined to be due on such returns, reports and
declarations, except those being contested in good faith and has set aside on its books provisions reasonably adequate for the payment of all taxes for periods subsequent to the periods to which such returns, reports or declarations apply. There are
no unpaid taxes in any material amount claimed to be due by the taxing authority of any jurisdiction, and the officers of the Company know of no basis for any such claim. The Company has not executed a waiver with respect to the statute of
limitations relating to the assessment or collection of any foreign, federal, state or local tax. Except as set forth on SCHEDULE 3(L), none of the Company’s tax returns is presently being audited by any taxing authority. 
 (m) CERTAIN TRANSACTIONS. Except as set forth on SCHEDULE 3(M) and except for arm’s length transactions pursuant to which the Company or any
of its Subsidiaries makes payments in the ordinary course of business upon terms no less favorable than the Company or any of its Subsidiaries could obtain from third parties and other than the grant of stock options disclosed on SCHEDULE 3(C), none
of the officers, directors, or employees of the Company is presently a party to any transaction with the Company or any of its Subsidiaries (other than for services as employees, officers and directors), including any contract, agreement or other
arrangement providing for the furnishing of services to or by, providing for rental of real or personal property to or from, or otherwise requiring payments to or from any officer, director or such employee or, to the knowledge of the Company, any
corporation, partnership, trust or other entity in which any officer, director, or any such employee has a substantial interest or is an officer, director, trustee or partner. 
 (n) DISCLOSURE. To the best of the Company’s knowledge, all information relating to or concerning the Company or any of its Subsidiaries set
forth in this Agreement and provided to each Buyer pursuant to Section 2(d) hereof and otherwise in connection with the transactions contemplated hereby is true and correct in all material respects and the Company has 

  

 14 








 
not omitted to state any material fact necessary in order to make the statements made herein or therein, in light of the circumstances under which they were
made, not misleading. No event or circumstance has occurred or exists with respect to the Company or any of its Subsidiaries or its or their business, properties, prospects, operations or financial conditions, which has not been publicly announced
or disclosed but under applicable law, rule or regulation, requires public disclosure or announcement by the Company (assuming for this purpose that the Company’s reports filed under the 1934 Act are being incorporated into an effective
registration statement filed by the Company under the 1933 Act). 
 (o) ACKNOWLEDGMENT REGARDING BUYER’S PURCHASE OF SECURITIES.
The Company acknowledges and agrees that each Buyer is acting solely in the capacity of arm’s length purchaser with respect to this Agreement and the transactions contemplated hereby. The Company further acknowledges that each Buyer is not
acting as a financial advisor or fiduciary of the Company (or in any similar capacity) with respect to this Agreement and the transactions contemplated hereby and that any statement made by each Buyer or any of its respective representatives or
agents in connection with this Agreement and the transactions contemplated hereby is not advice or a recommendation and is merely incidental to the Buyer’s purchase of the Securities and has not been relied upon by the Company, its officers or
directors in any way. The Company further represents to each Buyer that the Company’s decision to enter into this Agreement has been based solely on the independent evaluation of the Company and its representatives. 
 (p) NO INTEGRATED OFFERING. Neither the Company, nor any of its affiliates, nor any person acting on its or their behalf, has directly or
indirectly made any offers or sales of any security or solicited any offers to buy any security under circumstances that would require registration under the 1933 Act of the issuance of the Securities to any Buyer. The issuance of the Securities to
each Buyer will not be integrated with any other issuance of the Company’s securities for purposes of any stockholder approval provisions applicable to the Company or its securities. 
 (q) NO BROKERS. The identity of any brokers or placement agents that are receiving compensation in respect to this Offering, along with the amount
of cash, warrants or other consideration that compose any compensation to each such broker or placement agent, are disclosed in SCHEDULE 3(Q) hereto. Other than as set forth on SCHEDULE 3(Q), the Company has taken no action which would give rise to
any claim by any person for brokerage commissions, finder’s fees or similar payments relating to this Agreement or the transactions contemplated hereby. The Company shall indemnify and hold harmless each of Buyer, its employees, officers,
directors, agents, and partners, and their respective Affiliates, from and against all claims, losses, damages, costs (including the costs of preparation and attorney’s fees) and expenses suffered in respect of any such claimed or existing
fees. 
 (r) PERMITS; COMPLIANCE. The Company and each of its Subsidiaries is in possession of all franchises, grants, authorizations,
licenses, permits, easements, variances, exemptions, consents, certificates, approvals and orders necessary to own, lease and operate its properties and to carry on its business as it is now being conducted (collectively, the “COMPANY
PERMITS”), except where the failure to so possess any such Company Permits 

  

 15 








 
would not have a Material Adverse Effect, and there is no action pending or, to the knowledge of the Company, threatened regarding suspension or cancellation
of any of the Company Permits. To the best of the Company’s knowledge, neither the Company nor any of its Subsidiaries is in conflict with, or in default or violation of, any of the Company Permits, except for any such conflicts, defaults or
violations which, individually or in the aggregate, would not reasonably be expected to have a Material Adverse Effect. Since the beginning of the most recent fiscal quarter that began more than two (2) years prior to the Closing Date,
neither the Company nor any of its Subsidiaries has received any notification with respect to possible conflicts, defaults or violations of applicable laws, except for notices relating to possible conflicts, defaults or violations, which conflicts,
defaults or violations would not have a Material Adverse Effect. 
 (s) ENVIRONMENTAL MATTERS. 
 (i) Except as set forth in SCHEDULE 3(S), there are, to the Company’s knowledge, with respect to the Company or any of its Subsidiaries or any
predecessor of the Company, no past or present violations of Environmental Laws (as defined below), releases of any material into the environment, actions, activities, circumstances, conditions, events, incidents, or contractual obligations which
may give rise to any common law environmental liability or any liability under the Comprehensive Environmental Response, Compensation and Liability Act of 1980 or similar federal, state, local or foreign laws and neither the Company nor any of its
Subsidiaries has received any notice with respect to any of the foregoing, nor is any action pending or, to the Company’s knowledge, threatened in connection with any of the foregoing. The term “ENVIRONMENTAL LAWS” means all federal,
state, local or foreign laws relating to pollution or protection of human health or the environment (including, without limitation, ambient air, surface water, groundwater, land surface or subsurface strata), including, without limitation, laws
relating to emissions, discharges, releases or threatened releases of chemicals, pollutants contaminants, or toxic or hazardous substances or wastes (collectively, “HAZARDOUS MATERIALS”) into the environment, or otherwise relating to the
manufacture, processing, distribution, use, treatment, storage, disposal, transport or handling of Hazardous Materials, as well as all authorizations, codes, decrees, demands or demand letters, injunctions, judgments, licenses, notices or notice
letters, orders, permits, plans or regulations issued, entered, promulgated or approved thereunder. 
 (ii) Other than those that are or
were stored, used or disposed of in compliance with applicable law, no Hazardous Materials are contained on or about any real property currently owned, leased or used by the Company or any of its Subsidiaries, and no Hazardous Materials were
released on or about any real property previously owned, leased or used by the Company or any of its Subsidiaries during the period the property was owned, leased or used by the Company or any of its Subsidiaries, except in the normal course of the
Company’s or any of its Subsidiaries’ business. 
 (iii) Except as set forth in SCHEDULE 3(S), there are no underground storage
tanks on or under any real property owned, leased or used by the Company or any of its Subsidiaries that are not in compliance with applicable law. 
  

 16 








 (t) TITLE TO PROPERTY. The Company and its Subsidiaries have good and marketable title in fee
simple to all real property and good and marketable title to all personal property owned by them which is material to the business of the Company and its Subsidiaries, in each case free and clear of all liens, encumbrances and defects except such as
are described in SCHEDULE 3(T) or such as would not have a Material Adverse Effect. Any real property and facilities held under lease by the Company and its Subsidiaries are held by them under valid, subsisting and enforceable leases with such
exceptions as would not have a Material Adverse Effect. 
 (u) INSURANCE. The Company and each of its Subsidiaries are insured by
insurers of recognized financial responsibility against such losses and risks and in such amounts as management of the Company believes to be prudent and customary in the businesses in which the Company and its Subsidiaries are engaged. Neither the
Company nor any such Subsidiary has any reason to believe that it will not be able to renew its existing insurance coverage as and when such coverage expires or to obtain similar coverage from similar insurers as may be necessary to continue its
business at a cost that would not have a Material Adverse Effect. 
 (v) INTERNAL ACCOUNTING CONTROLS. The Company and each of its
Subsidiaries maintain a system of internal accounting controls sufficient, in the judgment of the Company’s board of directors, to provide reasonable assurance that (i) transactions are executed in accordance with management’s general
or specific authorizations, (ii) transactions are recorded as necessary to permit preparation of financial statements in conformity with generally accepted accounting principles and to maintain asset accountability, (iii) access to assets
is permitted only in accordance with management’s general or specific authorization and (iv) the recorded accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect
to any differences. 
 (w) FOREIGN CORRUPT PRACTICES. Neither the Company, nor any of its Subsidiaries, nor any director, officer,
agent, employee or other person acting on behalf of the Company or any Subsidiary has, in the course of his actions for, or on behalf of, the Company, used any corporate funds for any unlawful contribution, gift, entertainment or other unlawful
expenses relating to political activity; made any direct or indirect unlawful payment to any foreign or domestic government official or employee from corporate funds; violated or is in violation of any provision of the U.S. Foreign Corrupt Practices
Act of 1977; or made any bribe, rebate, payoff, influence payment, kickback or other unlawful payment to any foreign or domestic government official or employee. 
 (x) SOLVENCY. The Company (both before and after giving effect to the transactions contemplated by this Agreement) is solvent (i.e., its assets have a fair market value in excess of the amount required to pay
its probable liabilities on its existing debts as they become absolute and matured) and currently the Company has no information that would lead it to reasonably conclude that the Company would not have the ability to, nor does it intend to take any
action that would impair its ability to, pay its debts from time to time incurred in connection therewith as such debts mature. Except as disclosed in SCHEDULE 3(X), the Company did not receive a qualified opinion from its auditors with respect to
its most recent fiscal year end and does not anticipate or know of any basis upon which its auditors might issue a qualified opinion in respect of its current fiscal year. 
  

 17 








 (y) NO INVESTMENT COMPANY. The Company is not, and upon the issuance and sale of the Securities as
contemplated by this Agreement will not be, an “investment company” required to be registered under the Investment Company Act of 1940 (an “INVESTMENT COMPANY”). The Company is not controlled by an Investment Company. 

(z) NO MARKET MANIPULATION. The Company has not, and to its knowledge no one acting on its behalf has, (i) taken, directly or indirectly,
any action designed to cause or to result in, or that has constituted or which might reasonably be expected to constitute, the stabilization or manipulation of the price of any security of the Company to facilitate the sale or resale of any of the
Securities, (ii) sold, bid for, purchased, or paid anyone any compensation for soliciting purchases of, any of the Securities, or (iii) paid or agreed to pay to any person any compensation for soliciting another to purchase any other
securities of the Company. 
 (aa) STOP TRANSFER. The Securities, when issued, will be restricted securities. The Company will not
issue any stop transfer order or other order impeding the sale, resale or delivery of any of the Securities, except as may be required by any applicable federal or state securities laws and unless contemporaneous notice of such instruction is given
to the Buyer of such Securities. 
 (bb) NO UNDISCLOSED LIABILITIES. The Company has no liabilities or obligations which are material,
individually or in the aggregate, other than those incurred in the ordinary course of the Company’s businesses which have been disclosed in the Company’s public filings and which, individually or in the aggregate, would reasonably be
expected to have a Material Adverse Effect other than as set forth in SCHEDULE 3(BB). 
 (cc) NO UNDISCLOSED EVENTS OR CIRCUMSTANCES.
Other than events or circumstances which have been disclosed in the Company’s public filings, no event or circumstance has occurred or exists with respect to the Company or its businesses, properties, operations or financial condition, that,
under applicable law, rule or regulation, requires public disclosure or announcement prior to the date hereof by the Company but which has not been so publicly announced or disclosed in the Reports. 
 (dd) GOOD STANDING WITH ACCOUNTANTS AND LAWYERS. There are no disagreements of any kind presently existing, or reasonably anticipated by the
Company to arise, between the Company and the accountants and lawyers formerly or presently employed by the Company, with respect to disputes or conflicts over payment owed to such accountants and lawyers. Attached hereto as SCHEDULE DD is a signed
letter from the Company’s current outside law firm attesting to the facts relating to it relationship to the Company in the immediately preceding sentence (the “LAWYER LETTER”). 
 (ee) COMPANY ACKNOWLEDGMENT. The Company hereby acknowledges that each Buyer may elect to hold the Preferred Stock and the Warrants for various
periods of time, as permitted by the terms of the Transaction Documents and the 

  

 18 








 
Company further acknowledges that Buyer has made no representations or warranties, either written or oral, as to how long the Securities will be held by such
Buyer or regarding Buyer’s trading history or investment strategies, provided that this subsection does not supersede any of the representations made by the Buyer in Section 2. 
 (ff) DISCLOSURE. The Company confirms that neither it nor any other Person acting on its behalf has provided any of the Buyers or their
agents or counsel with any information that constitutes material, nonpublic information concerning the Company or its Subsidiaries other than the existence of the transactions contemplated by this Agreement or the other Transaction Documents. The
Company understands and confirms that each of the Buyers will rely on the foregoing representations in effecting transactions in securities of the Company. All disclosure provided to the Buyers regarding the Company, its business and the
transactions contemplated hereby, including the Schedules to this Agreement, furnished by or on behalf of the Company is true and correct and does not contain any untrue statement of a material fact or omit to state any material fact necessary in
order to make the statements made therein, in the light of the circumstances under which they were made, not misleading. Each press release issued by the Company or any of its Subsidiaries during the twelve (12) months preceding the date of
this Agreement did not at the time of release contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances
under which they were made, not misleading. No event or circumstance has occurred or information exists with respect to the Company or any of its Subsidiaries or its or their business, properties, prospects, operations or financial conditions,
which, under applicable law, rule or regulation, requires public disclosure or announcement by the Company but which has not been so publicly announced or disclosed. 
 (gg) ABSENCE OF CERTAIN COMPANY CONTROL PERSON ACTIONS OR EVENTS. To the Company’s knowledge, during the past five (5) years: 
 (i) No petition under the federal bankruptcy laws or any state insolvency law was filed by or against, and no receiver, fiscal agent or similar officer
was appointed by a court for the business or property of such Company Control Person, or any partnership in which he was a general partner at or within two years before the time of such filing, or any corporation or business association of which he
was an executive officer at or within two years before the time of such filing; 
 (ii) No Company Control Person was convicted in a
criminal proceeding or is a named subject of a pending criminal proceeding (excluding traffic violations and other minor offenses); 
 (iii)
No Company Control Person has been the subject of any order, judgment or decree, that was not subsequently reversed, suspended or vacated, of any court of competent jurisdiction, permanently or temporarily enjoining him from, or otherwise limiting,
the following activities: 
 (A) acting, as an investment advisor, underwriter, broker or dealer in securities, or as an affiliated person,
director or 

  

 19 








 
employee of any investment company, bank, savings and loan association or insurance company, as a futures commission merchant, introducing broker, commodity
trading advisor, commodity pool operator, floor broker, any other Person regulated by the Commodity Futures Trading Commission (“CFTC”) or engaging in or continuing any conduct or practice in connection with such activity; 
 (B) engaging in any type of business practice; or 
 (C) engaging in any activity in connection with the purchase or sale of any security or commodity or in connection with any violation of federal or state securities laws or federal commodities laws; 
 (iv) No Company Control Person has been the subject of any order, judgment or decree, not subsequently reversed, suspended or vacated, of any federal or
state authority barring, suspending or otherwise limiting for more than 60 days the right of such Company Control Person to engage in any activity described in paragraph (3) of this item, or to be associated with Persons engaged in any such
activity; or 
 (v) No Company Control Person was found by a court of competent jurisdiction in a civil action or by the CFTC or SEC to have
violated any federal or state securities law, and the judgment in such civil action or finding by the CFTC or SEC has not been subsequently reversed, suspended, or vacated. 
 For purposes hereof, “COMPANY CONTROL PERSON” means each director, executive officer, promoter, and such other Persons as may be deemed in
control of the Company pursuant to Rule 405 under the 1933 Act or Section 20 of the 1934 Act. 
 (hh) DTC STATUS. The
Company’s transfer agent is a participant in and the Common Stock is eligible for transfer pursuant to the Depository Trust Company Automated Securities Transfer Program. The name, address, telephone number, fax number, contact person and email
address of the Company transfer agent is set forth on SCHEDULE 3(HH) hereto. 
 (ii) SARBANES-OXLEY; INTERNAL ACCOUNTING CONTROLS. The
Company is in material compliance with all provisions of the Sarbanes-Oxley Act of 2002 which are applicable to it as of the Closing Date. 
 (jj) [INTENTIONALLY LEFT BLANK]. 
 (kk) REGISTRATION RIGHTS. Except as set forth in the SEC Reports and on SCHEDULE
3(KK) hereto, other than each of the Buyers, no Person has any right to cause the Company to effect the registration under the Securities Act of any securities of the Company. 
  

 20 








 (ll) TRANSACTIONS WITH AND OBLIGATIONS TO AFFILIATES. Except as set forth in the SEC
Documents filed at least ten days prior to the date hereof and other than the grant of stock options disclosed on SCHEDULE 3(LL), none of the officers, directors or employees of the Company or any of its Subsidiaries is presently a party to
any transaction with the Company or any of its Subsidiaries (other than for ordinary course services as employees, officers or directors), including any contract, agreement or other arrangement providing for the furnishing of services to or by,
providing for rental of real or personal property to or from, or otherwise requiring payments to or from any such officer, director or employee or, to the knowledge of the Company or any of its Subsidiaries, any corporation, partnership, trust or
other entity in which any such officer, director, or employee has a substantial interest or is an officer, director, trustee or partner. SCHEDULE 3(LL) sets forth any loans, payables, payments, transactions, debt or equity securities, or similar
agreements or obligations between the Company and any officers, directors, management or affiliates of the Company. 
 (mm) INDEBTEDNESS
AND OTHER CONTRACTS. All outstanding indebtedness (including but not limited to indebtedness convertible into equity) of the Company is set forth on SCHEDULE 3(MM). Except as disclosed in SCHEDULE 3(MM), neither the Company nor any
of its Subsidiaries (i) has any outstanding Indebtedness (as defined below), (ii) is a party to any contract, agreement or instrument, the violation of which, or default under which, by the other party(ies) to such contract, agreement or
instrument would result in a Material Adverse Effect, (iii) is in violation of any term of or in default under any contract, agreement or instrument relating to any Indebtedness, or (iv) is a party to any contract, agreement or instrument
relating to any Indebtedness, the performance of which, in the judgment of the Company’s officers, has or is expected to have a Material Adverse Effect. SCHEDULE 3(MM) provides a detailed description of the material terms of any such
outstanding Indebtedness. For purposes of this Agreement: (x) “INDEBTEDNESS” of any Person means, without duplication (A) all indebtedness for borrowed money, (B) all obligations issued, undertaken or assumed as the deferred
purchase price of property or services including (without limitation) “Capital Leases” in accordance with generally accepted accounting principles (other than trade payables entered into in the ordinary course of business), (C) all
reimbursement or payment obligations with respect to letters of credit, surety bonds and other similar instruments, (D) all obligations evidenced by notes, bonds, debentures or similar instruments, including obligations so evidenced incurred in
connection with the acquisition of property, assets or businesses, (E) all indebtedness created or arising under any conditional sale or other title retention agreement, or incurred as financing, in either case with respect to any property or
assets acquired with the proceeds of such indebtedness (even though the rights and remedies of the seller or bank under such agreement in the event of default are limited to repossession or sale of such property), (F) all monetary obligations
under any leasing or similar arrangement which, in connection with generally accepted accounting principles, consistently applied for the periods covered thereby, is classified as a capital lease, (G) all indebtedness referred to in clauses
(A) through (F) above secured by (or for which the holder of such Indebtedness has an existing right, contingent or otherwise, to be secured by) any mortgage, lien, pledge, charge, security interest or other encumbrance upon or in any
property or assets (including accounts and contract rights) owned by any Person, even though the Person which owns such assets or property has not assumed or become liable for the payment of such indebtedness, and (H) all Contingent Obligations
in respect of indebtedness or obligations of others of the kinds referred to in clauses (A) through (G) above; (y) “CONTINGENT 

  

 21 








 
OBLIGATION” means, as to any Person, any direct or indirect liability, contingent or otherwise, of that Person with respect to any indebtedness, lease,
dividend or other obligation of another Person if the primary purpose or intent of the Person incurring such liability, or the primary effect thereof, is to provide assurance to the obligee of such liability that such liability will be paid or
discharged, or that any agreements relating thereto will be complied with, or that the holders of such liability will be protected (in whole or in part) against loss with respect thereto; and (z) “PERSON” means an individual, a
limited liability company, a partnership, a joint venture, a corporation, a trust, an unincorporated organization and a government or any department or agency thereof. 
 (nn) CONDUCT OF BUSINESS. Neither the Company nor its Subsidiaries is in violation of any term of or in default under its Certificate of Incorporation, Bylaws or their organizational charter or bylaws,
respectively. Except as disclosed in SCHEDULE 3(NN), neither the Company nor any of its Subsidiaries is in violation of any judgment, decree or order or any statute, ordinance, rule or regulation applicable to the Company or its Subsidiaries,
and neither the Company nor any of its Subsidiaries will conduct its business in violation of any of the foregoing, except for possible violations which would not, individually or in the aggregate, have a Material Adverse Effect. Without limiting
the generality of the foregoing, the Company is not in violation of any of the rules, regulations or requirements of the Principal Market other than violations which could not reasonably be expected, individually or in the aggregate, to have a
Material Adverse Effect and has no knowledge of any facts or circumstances which would reasonably lead to delisting or suspension of the Common Stock by the Principal Market in the foreseeable future. Except as disclosed on SCHEDULE 3(NN)
since March 24, 2006, (i) the Common Stock has been designated for quotation on the Principal Market, (ii) trading in the Common Stock has not been suspended by the SEC or the Principal Market and (iii) the Company has received
no communication, written or oral, from the SEC or the Principal Market regarding the suspension or delisting of the Common Stock from the Principal Market, and the Company has not received any letters of inquiry from the SEC Division of Enforcement
or state securities regulators in the past 24 months related to any potential or alleged violation of state or federal securities laws. The Company and its Subsidiaries possess all certificates, authorizations and permits issued by the appropriate
regulatory authorities necessary to conduct their respective businesses, except where the failure to possess such certificates, authorizations or permits would not have, individually or in the aggregate, a Material Adverse Effect, and neither the
Company nor any such Subsidiary has received any notice of proceedings relating to the revocation or modification of any such certificate, authorization or permit. 
 (oo) ABSENCE OF CERTAIN CHANGES. Except as disclosed in SCHEDULE 3(H) or 3(OO) or in the SEC Documents, since the date of the Company’s most recent audited financial statements contained
in a Form 10-KSB, there has been no material adverse change and no material adverse development in the business, assets, properties, operations, condition (financial or otherwise), or results of operations of the Company. Except as disclosed in
SCHEDULE 3(OO), since the date of the Company’s most recent audited financial statements contained in a Form 10-K, neither the Company nor any of its Subsidiaries has (i) declared or paid any dividends on its Common Stock,
(ii) except as disclosed in the SEC Documents, sold any assets, individually or in the aggregate, in excess of $100,000 outside of the ordinary course of business or (iii) except as set forth in SCHEDULE 3(L) or in the SEC


  

 22 








 
Documents, had capital expenditures, individually or in the aggregate, in excess of $100,000. Except as set forth in SCHEDULE 3(OO), neither the
Company nor any of its Subsidiaries has taken any steps to seek protection pursuant to any bankruptcy law nor does the Company have any knowledge or reason to believe that its creditors intend to initiate involuntary bankruptcy proceedings or any
actual knowledge of any fact which would reasonably lead a creditor to do so. The Company and its Subsidiaries, individually and on a consolidated basis, are not as of the date hereof, and after giving effect to the transactions contemplated hereby
to occur at the Closing, will not be Insolvent (as defined below). For purposes of this Section 3(oo), “INSOLVENT” means (i) the present fair saleable value of the Company’s assets is less than the amount required to pay the
Company’s total Indebtedness, (ii) the Company is unable to pay its debts and liabilities, subordinated, contingent or otherwise, as such debts and liabilities become absolute and matured, (iii) the Company intends to incur or
believes that it will incur debts that would be beyond its ability to pay as such debts mature or (iv) the Company has unreasonably small capital with which to conduct the business in which it is engaged as such business is now conducted and is
proposed to be conducted. 
 (pp) NO UNDISCLOSED EVENTS, LIABILITIES, DEVELOPMENTS OR CIRCUMSTANCES. Except as disclosed in the
Disclosure Schedules, no event, liability, development or circumstance has occurred or exists, or is contemplated to occur with respect to the Company, its Subsidiaries or their respective business, properties, prospects, operations or financial
condition, that would be required to be disclosed by the Company under applicable securities laws on a registration statement on Form SB-2 or any other appropriate form filed with the SEC relating to an issuance and sale by the Company of its Common
Stock and which has not been publicly announced. 
 (qq) EMPLOYEE RELATIONS. 
 (i) Neither the Company nor any of its Subsidiaries is a party to any collective bargaining agreement or employs any member of a union. The Company and
its Subsidiaries believe that their relations with their employees are good. Except as disclosed in SCHEDULE 3(QQ), no executive officer of the Company or any of its Subsidiaries (as defined in Rule 501(f) of the 1933 Act) has notified the Company
or any such Subsidiary that such officer intends to leave the Company or any such Subsidiary or otherwise terminate such officer’s employment with the Company or any such Subsidiary. No executive officer of the Company or any of its
Subsidiaries, to the knowledge of the Company or any such Subsidiary, is, or is now expected to be, in violation of any material term of any employment contract, confidentiality, disclosure or proprietary information agreement, non-competition
agreement, or any other contract or agreement or any restrictive covenant, and, the continued employment of each such executive officer does not, subject the Company or any of its Subsidiaries to any liability with respect to any of the foregoing
matters. 
 (ii) The Company and its Subsidiaries are in compliance with all federal, state, local and foreign laws and regulations
respecting labor, employment and employment practices and benefits, terms and conditions of employment and wages and hours, except where failure to be in compliance would not, either individually or in the aggregate, reasonably be expected to result
in a Material Adverse Effect. 
  

 23 








 (rr) INTELLECTUAL PROPERTY RIGHTS. The Company and its Subsidiaries own or possess
adequate rights or licenses to use all trademarks, trade names, service marks, service mark registrations, service names, patents, patent rights, copyrights, inventions, licenses, approvals, governmental authorizations, trade secrets and other
intellectual property rights necessary to conduct their respective businesses as now conducted (“INTELLECTUAL PROPERTY RIGHTS”). Except as set forth in SCHEDULE 3(RR), none of the Company’s Intellectual Property Rights have
expired or terminated, or are expected to expire or terminate, within three years from the date of this Agreement. The Company does not have any knowledge of any infringement by the Company or its Subsidiaries of Intellectual Property Rights of
others. There is no claim, action or proceeding being made or brought, or to the knowledge of the Company, being threatened, against the Company or any of its Subsidiaries regarding its Intellectual Property Rights. The Company is unaware of any
facts or circumstances which might give rise to any of the foregoing infringements or claims, actions or proceedings. The Company and its Subsidiaries have taken reasonable security measures to protect the secrecy, confidentiality and value of all
of their Intellectual Property Rights. 
 (ss) OBLIGATIONS TO ISSUE ADDITIONAL SECURITIES. SCHEDULE 3(SS) lists all
outstanding debt or equity securities, warrants, options, or other Common Stock Equivalents, or contractual agreements of the Company that contain any provisions (“TRIGGERING PROVISIONS”) that could require the adjustment to conversion or
exercise prices of existing securities, or the issuance of additional securities triggered as a result of the issuance of securities by the Company or by the passage of time on or after the date of this Securities Purchase Agreement. 
 (tt) APPLICATION OF TAKEOVER PROTECTIONS. The Company and its Board of Directors have taken all necessary action, if any, in order to
render inapplicable any control share acquisition, business combination, poison pill (including any distribution under a rights agreement) or other similar antitakeover provision under the Company’s Certificate of Incorporation (or similar
charter documents) or the laws of its state of incorporation that is or could become applicable to the Buyers as a result of the Buyers and the Company fulfilling their obligations or exercising their rights under the Transaction Documents,
including without limitation as a result of the Company’s issuance of the Securities and the Buyers’ ownership of the Securities. 
 4. COVENANTS. 
 (a) BEST EFFORTS. The parties shall use their best efforts to satisfy timely each of the conditions
described in Sections 7 and 8 of this Agreement. 
 (b) FORM D; BLUE SKY LAWS. The Company agrees to file a Form D with respect to the
Securities as required under Regulation D and to provide a copy thereof to each Buyer promptly after such filing. The Company shall, on or before the Closing Date, take such action as the Company shall reasonably determine is necessary to qualify
the Securities for sale to the Buyer at the Closing pursuant to this Agreement under applicable securities or “blue sky” laws of the states of the United States (or to obtain an exemption from such qualification), and shall provide
evidence of any such action so taken to each Buyer on or prior to the Closing Date. 
  

 24 








 (c) REPORTING STATUS. The Company’s Common Stock is registered under Section 12(g) of
the 1934 Act. So long as any Buyer beneficially owns any of the Securities, the Company shall timely file all reports required to be filed with the SEC pursuant to the 1934 Act (“1934 ACT FILINGS”), and the Company shall not terminate its
status as an issuer required to file reports under the 1934 Act even if the 1934 Act or the rules and regulations thereunder would permit such termination. 
 (d) USE OF PROCEEDS. The Company shall use the proceeds from the sale of the Preferred Stock and the Warrants in the manner set forth in SCHEDULE 4(D) attached hereto and made a part hereof and, except as
otherwise expressly specified in SCHEDULE 4(D), the Company shall not use any of such proceeds (i) to repay any of its corporate debt or other Indebtedness, (ii) to redeem any Common Stock or Common Stock Equivalents, to settle any
outstanding litigation or (iii) to repay any debt or obligation to any officer, director or manager of the Company, or any of their affiliates or family members (collectively, “INSIDERS”). From the date hereof until the date that
Preferred Stock with an aggregate Stated Value of at least one million dollars ($1,000,000) is no longer outstanding, in the event that the Company raises capital through the issuance of debt or equity, or other Common Stock Equivalents, the Company
shall be prohibited from using in excess of ten percent (10%) of the proceeds of any such issuances for the repayment of the then outstanding indebtedness to any Insider or the payment of salaries (other than salaries for the current pay
period) or bonuses to any Insiders that have accrued and become payable prior to the date of such financing but that had not been paid. 
 (e) CAPITAL RAISING LIMITATIONS; RIGHT OF PARTICIPATION. 
 (i) Lock-up of Issuance of Securities. Except for the
Series B Preferred Stock issuable hereunder, except for Exempt Issuances, except for the Lock-Up Exceptions, as defined below, and except for the transactions or other issuances of securities by the Company to the Buyers as contemplated by the
Transaction Documents, during the period that Preferred Stock with an aggregate Stated Value of at least one million dollars ($1,000,000) remains outstanding (the “LIMITATION PERIOD”), neither the Company nor any Subsidiary shall issue
shares of Common Stock or Common Stock Equivalents (the “LOCK-UP”). Notwithstanding the above, the Company may issue: (A) in any combination of private offerings or underwritten public offerings, up to $50 million of Straight Common
Stock (as defined below) during any rolling twelve (12) calendar month period following the Closing Date, which Common Stock may be issued at a purchase price of not less than 75% of the Market Price (as defined in the Certificate of
Designation) at the time of issuance (collectively, “COMMON STOCK LOCK-UP EXCEPTIONS”), and (B) an amount of preferred stock and associated warrants to purchase common stock (the “PREFERRED STOCK LOCK-UP EXCEPTIONS”),
including but not limited to any Series A preferred stock issued hereafter and any other series of preferred stock issued hereafter, not to exceed an amount equal to $10,000,000 minus the total aggregate Stated Value of Series B Preferred Stock sold
pursuant to the Securities Purchase Agreement to Buyers other than Series A Exchange Investors. For purposes hereof, “STRAIGHT 

  

 25 








 
COMMON STOCK” shall mean Common Stock that is issued by the Company to a purchaser, and is not accompanied by any warrants, options, convertible
securities or any other Common Stock Equivalents. Common Stock Lock-Up Exceptions and Preferred Stock Lock-Up Exceptions are collectively referred to herein as “LOCK-UP EXCEPTIONS.” It is expressly agreed and understood that the
characterization of an issuance of securities as a Lock-Up Exception does not cause such issuance to be exempt from any provisions of the Transaction Documents, including but not limited to (A) the provisions in the Certificate of Designation
regarding adjustments to the Conversion Price of the Preferred Stock and the provisions in the Warrant regarding adjustments to the Exercise Price of the Warrant, (B) the provisions in the Certificate of Designation and the Warrants defining a
25% Aggregate Issuance (as defined in the Certificate of Designation and the Warrant, respectively), or (C) the MFN Securities Exchange Provision of Section 4(e)(iv). 
 (ii) Capital Raising Limitations. During the period that Preferred Stock with an aggregate Stated Value of at least one million dollars
($1,000,000) remains outstanding, or so long as any of the Warrants to purchase at least 100,000 shares of Common Stock remain outstanding, notwithstanding whether or not an issuance of securities is an Exempt Issuance, the Company shall not issue
or sell, or agree to issue or sell Variable Equity Securities (as defined below), or any securities of the Company pursuant to an Equity Line (as defined below) structure or format or any securities of the Company in exchange for goods or services,
without obtaining the prior written approval of the Required Holders , with the exception of any such agreements, transactions or Equity Lines existing as of the date hereof. For purposes hereof, an “EQUITY LINE” shall mean a transaction
involving a written agreement between the Company and an investor or underwriter whereby the Company has the right to “put” its securities to the investor or underwriter over an agreed period of time and at an agreed price or price
formula. For purposes hereof, the following shall be collectively referred to herein as, the “VARIABLE EQUITY SECURITIES”: (A) any debt or equity securities or other Common Stock Equivalents which are convertible into, exercisable or
exchangeable for, or carry the right to receive additional shares of Common Stock either (1) at any conversion, exercise or exchange rate or other price that is based upon and/or varies with the trading prices of or quotations for Common Stock
at any time after the initial issuance of such debt or equity security, or (2) with a fixed conversion, exercise or exchange price that is subject to being reset at some future date at any time after the initial issuance of such debt or equity
security due to a change in the market price of the Company’s Common Stock since date of initial issuance, or (B) any amortizing convertible security which amortizes prior to its maturity date, where the Company has the option to make such
amortization payments in shares of Common Stock (whether or not such payments in stock are subject to certain equity conditions), or (C) any debenture, preferred stock or other Common Stock Equivalent that is accompanied by a number of warrants
greater than 50% (100%, in the case of preferred stock issued under the Preferred Stock Lock-Up Exceptions) of the original principal amount, divided by the Market Price at the time of closing of such debenture or preferred stock, or (D) any
Common Stock that is sold at a discount to the Market Price at the time of closing that is greater than 25%, (E) any adjustable warrant (other than warrants accompanying preferred stock issued under the Preferred Stock Lock-Up Exceptions) where
the number of shares issuable thereunder is subject to increase, (F) any Common Stock that is accompanied by a number of warrants greater than the number of shares of Common Stock sold by the Company in such transaction, (G) any warrant,
convertible security or other 

  

 26 








 
Common Stock Equivalent with a conversion, exercise or exchange price that is set at a price that represents a discount to the Market Price at the time of
closing of such warrant, convertible security or other Common Stock Equivalent that is greater than 25%, (H) any note, debenture or other debt obligation that is accompanied by shares of Common Stock for which the additional consideration paid
per share of Common Stock is less than 90% of the Market Price at the time of closing. For purposes of the above, the “MARKET PRICE” at time of closing shall mean the Market Price, as defined in the Certificate of Designation. 

 

 27 








 (iii) Buyer’s Right of Participation in Future Financings.  
 (A) From the date hereof and during the period that any portion of the Preferred Stock is outstanding, upon any financing by the Company or any of its
subsidiaries (each, a “SUBSEQUENT FINANCING”) of Common Stock or Common Stock Equivalents (as defined in Section 1(a)), excluding any securities issued pursuant to the Offering described in this Agreement, each Buyer shall have the
right to participate in up to the Buyer’s Participation Maximum (as defined below) of the Subsequent Financing, provided that any securities issued to the Buyer hereunder, and any securities issuable pursuant to the conversion or exercise of
such securities, shall be subject to the Beneficial Ownership Limitation. 
 (B) At least ten (10) days prior to the closing of the
Subsequent Financing, the Company shall deliver to each Buyer a written notice of its intention to effect a Subsequent Financing (an “ADVANCE NOTICE OF FINANCING”), which Advance Notice of Financing shall ask such Buyer if it wants to
review the details of such financing (such additional notice, a “SUBSEQUENT FINANCING NOTICE”). Upon the request of a Buyer, and only upon a request by such Buyer, for a Subsequent Financing Notice, the Company shall promptly, but no later
than one (1) Trading Day after such request, deliver a Subsequent Financing Notice to such Buyer. The Subsequent Financing Notice shall describe in reasonable detail the proposed terms of such Subsequent Financing, the amount of proceeds
intended to be raised thereunder, the Person with whom such Subsequent Financing is proposed to be effected, and attached to which shall be a term sheet or similar document relating thereto. 
 (C) Any Buyer desiring to participate in such Subsequent Financing must provide written notice to
the Company by not later than 5:30 p.m. (New York City time) on the tenth (10th) Trading Day after such Buyer
has received the Advance Notice of Financing that the Buyer is willing to participate in the Subsequent Financing, the amount of the Buyer’s participation, and that the Buyer has such funds ready, willing, and available for investment on the
terms set forth in the Subsequent Financing Notice. If the Company receives no notice from a Buyer as of such tenth (10th) Trading Day, such Buyer shall be deemed to have notified the Company that it does not elect to participate. 
 (D) If by 5:30 p.m. (New York City time) on the tenth (10th) Trading Day after all of the requesting Buyers have received the Advance Notice of Financing, notifications by the Buyers of their willingness
to participate in the Subsequent Financing (or to cause their designees to participate) is, in the aggregate, less than the total amount of the Subsequent Financing, then the Company may effect the remaining portion of such Subsequent Financing on
the terms and to the Persons set forth in the Subsequent Financing Notice. 
 (E) If by 5:30 p.m. (New York City time) on the tenth
(10th) Trading Day after all of the Buyers have received the Advance Notice of Financing, the Company receives responses to a Subsequent Financing Notice from Buyers seeking to purchase more than the aggregate amount of the Subsequent
Financing, each such Buyer shall have the right to purchase up to (the “BUYER’S PARTICIPATION MAXIMUM”) (a) their Pro Rata Portion (as defined below) of the Subsequent Financing, plus (b) a pro rata amount (based upon the
relative amount of the participating Buyers’ respective Pro Rata Portions) of the aggregate of 

  

 28 








 
the unused Pro Rata Portions of the other Buyers. For purposes hereof, “PRO RATA PORTION” shall mean the ratio of (x) the Subscription
Amount of Securities purchased on the Closing Date by a Buyer participating under this Section 4(e)(iii)(E) and (y) the sum of the aggregate Subscription Amounts of Securities purchased on the Closing Date by all Buyers participating under
this Section 4(e)(iii)(E). 
 (F) For purposes of clarity, in the event that there is any amount of a Subsequent Financing that is not
requested to be purchased by a Buyer, then any other Buyer shall have the right to purchase such remaining amount of the Subsequent Financing. 
 (G) The Company must provide the Buyers with a second Subsequent Financing Notice, and the Buyers will again have the right of participation set forth above in this Section 4(e)(iii)(E), if the Subsequent Financing subject to the
initial Subsequent Financing Notice is not consummated for any reason on the terms set forth in such Subsequent Financing Notice within thirty (30) Trading Days after the date of the initial Subsequent Financing Notice. 
 (iv) Most Favored Nation (MFN) Securities Exchange Provision. From the date hereof until the date when such Buyer holds less than 20% in Stated
Value of Preferred Stock originally purchased by such Buyer hereunder, if the Company effects a Subsequent Financing (expressly including but not limited to offerings of preferred stock that constitute Preferred Stock Lock-Up Exceptions), each Buyer
may elect, in its sole discretion, to exchange all or some of the Preferred Stock then held by such Buyer for any securities or units issued in a Subsequent Financing on a $1.00 for $1.00 basis based on the outstanding principal amount of such
Preferred Stock, along with any accrued but unpaid interest, liquidated damages and other amounts owing thereon, and the effective price at which such securities were sold in such Subsequent Financing; PROVIDED, HOWEVER, that this
Section 4(e)(iv) shall not apply with respect to (a) an Exempt Issuance or (b) a firm commitment underwritten public offering of Common Stock with a reputable national underwriter. The Company shall provide each Buyer with notice of
any such Subsequent Financing in the manner set forth in Section 4(e)(iv), provided that following such an exchange, the Holder shall retain all of its unconverted Warrants. 
 (v) Injunctive Relief. The Company acknowledges that a breach by it of its obligations under this Subsection 4(e) or its obligations under
Section 4(m) will cause irreparable harm to Buyer, by vitiating the intent and purpose of the transactions contemplated hereby. Accordingly, the Company acknowledges that the remedy at law for a breach of its obligations under this Subsection
4(e) or a breach of its obligations under Subsection 4(m) will be inadequate and agrees, in the event of a breach or threatened breach by the Company of the provisions of this Agreement, that Buyer shall be entitled, in addition to all other
available remedies in law or in equity, to an injunction or injunctions to prevent or cure any breaches of the provisions of this Subsection 4(e) or of Subsection 4(m) and to enforce specifically the terms and provisions of this Agreement, without
the necessity of showing economic loss and without any bond or other security being required. Specifically, the Buyer shall be entitled to injunctive relief to cause the court to rescind any financing or financings or other transactions between the
Company and a third party that are in violation of subsection 4(e) or subsection 4(m) the Buyer 

  

 29 








 
shall be entitled to injunctive relief to cause the court to rescind any financing or financings between the Company and a third party that are in violation
of subsection 4(e) or subsection 4(m). 
 (f) SECURITIES LAWS DISCLOSURE;
PUBLICITY. The Company shall, by 3:00 p.m. New York City time on the fourth (4th) Business Day following
the Closing Date, issue a Current Report on Form 8-K, disclosing the material terms of the transactions contemplated hereby and including the Transaction Documents as exhibits thereto. The Company and each Buyer shall consult with each other in
issuing any other press releases with respect to the transactions contemplated hereby, and neither the Company nor any Buyer shall issue any such press release or otherwise make any such public statement without the prior consent of the Company,
with respect to any press release of any Buyer, or without the prior consent of each Buyer, with respect to any press release of the Company, which consent shall not unreasonably be withheld or delayed, except if such disclosure is required by law,
in which case the disclosing party shall promptly provide the other party with prior notice of such public statement or communication. Notwithstanding the foregoing, the Company shall not publicly disclose the name of any Buyer, or include the name
of any Buyer in any filing with the Commission or any regulatory agency or any market or exchange, without the prior written consent of such Buyer, except (i) as required by federal securities law in connection with (A) any registration
statement contemplated by the Registration Rights Agreement and (B) the filing of final Transaction Documents (including signature pages thereto) with the SEC and (ii) to the extent such disclosure is required by law or regulations of the
Principal Market, in which case the Company shall provide the Buyers with prior notice of such disclosure permitted under this subclause (ii). 
 (g) FINANCIAL INFORMATION. The Company agrees to send, or make available via public filings on the internet, the following reports to each Buyer until such Buyer transfers, assigns, or sells all of the Securities: (i) within ten
(10) days after the filing with the SEC, a copy of its Annual Report on Form 10-KSB, its Quarterly Reports on Form 10-QSB and any Current Reports on Form 8-KSB; (ii) within one (1) day after release, copies of all press releases
issued by the Company or any of its Subsidiaries; and (iii) contemporaneously with the making available or giving to the stockholders of the Company, copies of any notices or other information the Company makes available or gives to such
stockholders. 
 (h) AUTHORIZATION AND RESERVATION OF SHARES. 
 (i) Authorization and Reservation Requirements. The Company represents that it has at least 100,000,000 authorized shares of Common Stock
and covenants that it will initially reserve (the “INITIAL SHARE RESERVATION”) from its authorized and unissued Common Stock a number of shares of Common Stock equal to at least one and one-half (1.5) times the aggregate Stated Value
of the Preferred Stock, divided by the Conversion Price in effect on the date of the Initial Share Reservation, free from preemptive rights, to provide for the issuance of Common Stock upon the conversion of the Preferred Stock and shall initially
reserve an additional number of shares equal to the Warrant Amount, free from preemptive rights, to provide for the issuance of Common Stock upon the exercise of the Warrants. The Company further covenants that, beginning on the date hereof, and
continuing throughout the period the 

  

 30 








 
conversion right exists, the Company shall at all times have authorized, and reserved (the “ONGOING SHARE RESERVATION REQUIREMENT”) for the purpose
of issuance, a sufficient number of shares of Common Stock to provide for the full conversion or exercise of the outstanding portion of the Preferred Stock and Warrants and issuance of the Conversion Shares and Warrant Shares in connection therewith
(based on the Conversion Price (as defined in the Certificate of Designation) in effect from time to time and the Exercise Price of the Warrants in effect from time to time). The Company shall not reduce the number of shares of Common Stock reserved
for issuance upon conversion of or otherwise pursuant to the Certificate of Designation and exercise of or otherwise pursuant to the Warrants without the consent of the Buyers. The Company shall at all times maintain the number of shares of Common
Stock so reserved for issuance at no less than 100% of the number that is then actually issuable upon full conversion of the Preferred Stock (based on the Conversion Price (as defined in the Certificate of Designation) in effect from time to time)
and full exercise of the Warrants (based on the Exercise Price of the Warrants in effect from time to time). 
 (ii) Stockholder
Approval. If at any time the number of shares of Common Stock authorized and reserved for issuance is below the number of Conversion Shares issued and issuable upon conversion of or otherwise pursuant to the Certificate of Designation (based on
the Conversion Price (as defined in the Certificate of Designation) in effect from time to time) and Warrant Shares issued or issuable upon exercise of or otherwise pursuant to the Warrants (based on the Exercise Price of the Warrants in effect from
time to time), together with the Payment Shares and any other shares of Common Stock issued or issuable pursuant to the terms of the Transaction Documents, the Company will promptly take all corporate action necessary to authorize and reserve a
sufficient number of shares, including, without limitation, calling a special meeting of stockholders to authorize additional shares to meet the Company’s obligations under this Section 4(h), in the case of an insufficient number of
authorized shares, and using its best efforts to obtain stockholder approval of an increase in such authorized number of shares. 
 (i) CERTAIN TRADING ACTIVITIES. Anytime during the period that any Preferred Stock or Warrants are outstanding, the Buyer and its Affiliates will not enter into or effect, or attempt to induce any third party to enter into or
effect, any “short sales” (as such term is defined in Rule 200 of Regulation SHO) of the Common Stock or hedging transaction which, in either case, establishes a net short position with respect to the Common Stock, where “net short
position” means having a contractual obligation to deliver a greater number of shares of Common Stock than such Buyer beneficially owns long, which includes without limitation shares of Common Stock held long and shares of Common Stock issuable
upon exercise, conversion or exchange of Company securities held by such Buyer (whether or not then convertible, exercisable or exchangeable and without regard to any limitation on beneficial ownership or restrictions on conversion, exercise or
exchange), including the Preferred Stock and Warrants. For the purposes of this Agreement, an “AFFILIATE” of any person or entity means any other person or entity directly or indirectly controlling, controlled by or under direct or
indirect common control with such person or entity. 
 (j) LISTING. The Company shall use its best efforts to promptly secure the
listing of the Conversion Shares and Warrant Shares upon each national securities exchange or 

  

 31 








 
automated quotation system, if any, upon which shares of Common Stock are then listed (subject to official notice of issuance) and, so long as any Buyer owns
any of the Securities, shall maintain, so long as any other shares of Common Stock shall be so listed, such listing of all Conversion Shares from time to time issuable upon conversion of or otherwise pursuant to the Certificate of Designation and
all Warrant Shares from time to time issuable upon exercise of or otherwise pursuant to the Warrants. The Company will use its best efforts to obtain and, so long as any Buyer owns any of the Securities, maintain the listing and trading of its
Common Stock on an Eligible Market (whichever Eligible Market is at the time the principal trading exchange or market for the Common Stock is referred to herein as the “PRINCIPAL MARKET”), and will comply in all respects with the
Company’s reporting, filing and other obligations under the bylaws or rules of the National Association of Securities Dealers (“NASD”) and such exchanges, as applicable. The Company shall promptly provide to Buyer copies of any
notices it receives from the PRINCIPAL MARKET and any other exchanges or quotation systems on which the Common Stock is then listed regarding the continued eligibility of the Common Stock for listing on such exchanges and quotation systems.

 (k) CORPORATE EXISTENCE. So long as a Buyer beneficially owns any portion of the Preferred Stock or Warrants, the Company shall
maintain its corporate existence in good standing and remain a “REPORTING ISSUER” (defined as a Company which files periodic reports under the Exchange Act). 
 (l) NO INTEGRATION. The Company shall not make any offers or sales of any security (other than the Securities) under circumstances that would require registration of the Securities being offered or sold
hereunder under the 1933 Act or cause the offering of the Securities to be integrated with any other offering of securities by the Company, unless a registration statement is in effect with respect to any such offers or sales or, unless such
integrated offering would nonetheless be exempt from registration under the 1933 Act. 
 (m) LIMITATION ON SALE OR DISPOSITION OF
INTELLECTUAL PROPERTY. So long as Preferred Stock with an aggregate Stated Value of at least one million dollars ($1,000,000) remains outstanding, or so long as Warrants to purchase at least 100,000 shares of Common Stock remain outstanding, the
Corporation shall not sell, convey, dispose of, spin off or assign any or all of its Intellectual Property (including but not limited to the Intellectual Property set forth in SCHEDULE 4(M) hereof), or the rights to receive proceeds from patent
licensing agreements, patent infringement litigation or other litigation related to such intellectual property (collectively, the “INTELLECTUAL PROPERTY RIGHTS”), in each case without the written consent of the Required Holders, provided
that the Company may, without the Buyer’s Written Consent, enter into one or more licensing agreements with respect to its Intellectual Property so long as such licensing agreements exceed $5 million per calendar year and so long as such
agreements are not with any affiliate (as such term is defined in Rule 501(b) of Regulation D) of the Company or with any relative of, or entity controlled by, or any entity 10% or more of which is owned by, any officer, director, employee or former
employee of the Company, provided, further, that the Company shall not be subject to the restrictions of this Section 4(m) if the cash consideration received by the Company in exchange for such Intellectual Property Rights exceeds $50 million.

  

 32 








 (n) LIMITATION ON RATE OF ISSUANCE OF SHARES. The parties agree that, if by virtue of this
AGREEMENT, or by virtue of any other agreement between the parties, Holder becomes entitled to receive from the Company a number of shares of Common Stock of the Company (collectively, “ISSUABLE SECURITIES”), such that the sum of
(1) the number of shares of Common Stock of the Company beneficially owned by HOLDER and any applicable affiliates (other than shares of Common Stock which may be deemed beneficially owned through the ownership of the unconverted portion of the
Preferred Stock, the unexercised Warrants or the unexercised or unconverted portion of any other security of HOLDER subject to a limitation on conversion or exercise analogous to the limitations contained herein)(collectively, the “BENEFICIALLY
OWNED SHARES”) and (2) the number Issuable Securities described above, with respect to which the determination of this proviso is being made, would result in beneficial ownership by the Holder and its affiliates of more than 4.99% of the
outstanding shares of Common Stock (the “4.99% BENEFICIAL OWNERSHIP LIMITATION”), then the Company shall immediately deliver to Holder the number of shares of Common Stock of the Company, that can be issued without exceeding the 4.99%
Beneficial Ownership Limitation, and the Company shall not issue shares of Common Stock to the Buyer in excess of the Beneficial Ownership Limitation. 
 For purposes of the proviso to the immediately preceding sentence, (i) beneficial ownership shall be determined by the Holder in accordance with Section 13(d) of the Exchange Act and Regulations 13D-G
thereunder, except as otherwise provided in clause (1) of such proviso to the immediately preceding sentence, and PROVIDED THAT the 4.99% Beneficial Ownership Limitation shall be conclusively satisfied if the applicable notice from Holder
includes a signed representation by the Holder that the issuance of the shares in such notice will not violate the 4.99% Beneficial Ownership Limitation, and the Company shall not be entitled to require additional documentation of such satisfaction.

 The parties agree that, in the event that the Company receives any tender offer or any offer to enter into a merger with another entity
whereby the Company shall not be the surviving entity (an “OFFER”), or in the event the Company is issuing Default Shares (as defined in the Certificate of Designation) to the Buyer, then “4.99%” shall be automatically revised
immediately after such offer to read “9.99%” each place it occurs in the first two paragraphs of this Section 4(n) above. Notwithstanding the above, Holder shall retain the option to either exercise or not exercise its option(s) to
acquire Common Stock pursuant to the terms hereof after an Offer. In addition, the 4.99% Beneficial Ownership Limitation provisions of this Section 7(a)(ii) may be waived by such Holder, at the election of such Holder, upon not less than 61
days’ prior notice to the Company, to change the 4.99% Beneficial Ownership Limitation to 9.99% of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock upon conversion of
the Preferred Stock held by the Holder or upon exercise of a Warrant held by the Holder, as applicable, and the provisions of this Section 4(n) shall continue to apply. The limitations on conversion set forth in this subsection are referred to
as the “BENEFICIAL OWNERSHIP LIMITATION.” Upon such a change by a Holder of the Beneficial Ownership Limitation from such 4.99% Beneficial Ownership Limitation to such 9.99% limitation, the Beneficial Ownership Limitation may not be
further waived by such Holder. 
  

 33 








 The provisions of this paragraph shall be construed and implemented in a manner otherwise than in strict
conformity with the terms of this Section 4(c) to correct this paragraph (or any portion hereof) which may be defective or inconsistent with the intended Beneficial Ownership Limitation herein contained or to make changes or supplements
necessary or desirable to properly give effect to such limitation. 
 Maximum Exercise of Rights. In the event the Buyer notifies the Company
that the exercise of the rights described herein or in the Warrants, or the issuance of Payment Shares or other shares of Common Stock issuable to the Holder under the terms of the Transaction Documents (collectively, “ISSUABLE SHARES”)
would result in the issuance of an amount of Common Stock of the Company that would exceed the maximum amount that may be issued to a Buyer calculated in the manner described in Section 4(n) of this Agreement, then the issuance of such
additional shares of Common Stock of the Company to such Buyer will be deferred in whole or in part until such time as such Buyer is able to beneficially own such Common Stock without exceeding the maximum amount set forth calculated in the manner
described in herein. The determination of when such Common Stock may be issued shall be made by each Buyer as to only such Buyer. 
 (o)
APPOINTMENT OF DIRECTORS UPON CONTINUING DEFAULT. For so long as Preferred Stock having an aggregate Stated Value of at least one million dollars ($1,000,000) remains outstanding (i) if any Event of Default (as defined in the Certificate of
Designation) remains uncured for an aggregate of thirty (30) consecutive days or more, the Buyers, at their option, may recommend one nominee for the Company’s Board of Directors (such nomination based upon a majority vote of the Buyers,
where each Buyer receives a number of votes in proportion to the then outstanding Stated Value of its Preferred Stock), (ii) if any Event of Default remains uncured for an aggregate of thirty (30) consecutive days or more following the
recommended nomination pursuant to clause (i) immediately above, the Buyers, at their option, may recommend a second nominee for the Company’s Board of Directors (using the above described nomination procedure), and (iii) if any Event
of Default remains uncured for an aggregate of thirty (30) consecutive days or more following the recommended nomination pursuant to clause (ii) immediately above, the Buyers, at their option, may (on one or more occasions thereafter
anytime thereafter that the Buyer’s Nominees do not equal a majority of the Company’s directors until cured) recommend an additional number of nominees to the Company’s Board of Directors (using the above described nomination
procedure), such that the Buyers’ nominees shall constitute a majority of the Company’s Board of Directors (each such nominee referred to singularly as a “BUYERS NOMINEE” and collectively as the “BUYERS’
NOMINEES”). The Company agrees that its Board of Directors, or the Nominating Committee of the Board, as applicable, shall appoint as members of the Company’s Board of Directors the number of Buyers’ Nominee’s required pursuant
to the immediately preceding sentence. After such appointment, the Company and its Board of Directors shall use their best efforts to obtain stockholder ratification of the appointment of the Buyers’ Nominees at the next stockholder meeting. At
such time as the outstanding amount of Preferred Stock has an aggregate Stated Value of less than $1,000,000, the Buyers agree to cause the Buyers’ Nominees to resign from the Board of Directors. 
  

 34 








 (p) EQUAL TREATMENT OF BUYERS. The terms of Securities issued to Buyers per the terms of this
Agreement and the Transaction Documents shall be identical in all material respects. In addition, neither the Company nor any of its affiliates shall, directly or indirectly, pay or cause to be paid any consideration (immediate or contingent),
whether by way of interest, fee, payment for the redemption, conversion of the Notes or exercise of the Warrants, or otherwise, to any Buyer or holder of Securities, for or as an inducement to, or in connection with the solicitation of, any consent,
waiver or amendment of any terms or provisions of the Transaction Documents, unless such consideration is required to be paid to all Buyers or holders of Securities bound by such consent, waiver or amendment. The Company shall not, directly or
indirectly, redeem any Securities unless such offer of redemption is made pro rata to all Buyers or holders of Securities, as the case may be, on identical terms. For clarification purposes, this provision constitutes a separate right granted by the
Company to each Buyer of Securities and negotiated separately by each Buyer, is intended for the Company to treat the Buyers as a class, and shall not in any way be construed as the Buyers acting in concert or as a group with respect to the
purchase, disposition or voting of Securities or otherwise. 
 (q) LEGAL AND DUE DILIGENCE FEES. The Company shall pay to
BridgePointe Master Fund Ltd. (the “LEAD INVESTOR”) a cash fee of $25,000 (the “LEAD INVESTOR’S FEE”) at closing as reimbursement for legal services rendered by its attorneys in connection with this Agreement and the
purchase and sale of the Preferred Stock and Warrants and as reimbursement for due diligence expenses. The Lead Investor may withhold such amount out of the Purchase Price for its Preferred Stock. 
 (r) LIMITED STANDSTILL. The Company will deliver to the Buyers on or before the Closing Date and enforce the provisions of irrevocable
standstill agreements (“LIMITED STANDSTILL AGREEMENTS”) in the form annexed hereto as EXHIBIT F with the Insiders that are identified on SCHEDULE 4(r) hereto (the “DESIGNATED INSIDERS”). 
 (s) NON-PUBLIC INFORMATION. The Company covenants and agrees that from and after the date hereof, neither it nor any other Person acting on its
behalf will provide any Buyer or its agents or counsel with any information that the Company believes constitutes material non-public information, unless prior thereto such Buyer shall have executed a written agreement regarding the confidentiality
and use of such information. The Company understands and confirms that each Buyer shall be relying on the foregoing representations in effecting transactions in securities of the Company. In the event of a breach of the foregoing covenant by the
Company, or any of its Subsidiaries, or any of its or their respective officers, directors, employees and agents, in addition to any other remedy provided herein or in the Transaction Documents, the Company shall publicly disclose any material,
non-public information in a Form 8-K within five (5) Business Days of the date that it discloses such information to the Buyer. In the event that the Company discloses any material, non-public information to the Buyer and fails to publicly file
a Form 8-K in accordance with the above, a Buyer shall have the right to make a public disclosure, in the form of a press release, public advertisement or otherwise, of such material, nonpublic information without the prior approval by the Company,
its Subsidiaries, or any of its or their respective officers, directors, employees or agents. No Buyer shall have any liability to the Company, its Subsidiaries, or any of its or their respective officers, directors, employees, stockholders or
agents, for any such disclosure. The Company understands and confirms that each Buyer shall be relying on the foregoing representations in effecting transactions in securities of the Company. 
  

 35 








 (t) ADDITIONAL REGISTRATION STATEMENTS. Except as otherwise set forth on SCHEDULE 4(T),
until the Effective Date, the Company will not file a registration statement under the 1933 Act relating to securities that are not the Securities. 
 (u) TRANSACTIONS WITH AFFILIATES. Without the consent of the Required Holders, until the date that Preferred Stock with an aggregate Stated Value of at least one million dollars ($1,000,000) is no longer outstanding, the Company
shall not, and shall cause each of its Subsidiaries not to, enter into, amend, modify or supplement, or permit any Subsidiary to enter into, amend, modify or supplement any agreement, transaction, commitment, or arrangement with any of its or any
Subsidiary’s officers, directors, person who were officers or directors at any time during the previous two (2) years, stockholders who beneficially own five percent (5%) or more of the Common Stock, or Affiliates (as defined below)
or with any individual related by blood, marriage, or adoption to any such individual or with any entity in which any such entity or individual owns a five percent (5%) or more beneficial interest (each a “RELATED PARTY”), except for
customary employment arrangements and benefit programs on reasonable terms. “AFFILIATE” for purposes hereof means, with respect to any person or entity, another person or entity that, directly or indirectly, (i) has a ten percent
(10%) or more equity interest in that person or entity, (ii) has ten percent (10%) or more common ownership with that person or entity, (iii) controls that person or entity, or (iv) shares common control with that person or
entity. “CONTROL” or “CONTROLS” for purposes hereof means that a person or entity has the power, direct or indirect, to conduct or govern the policies of another person or entity. 
 (v) CERTIFICATE OF DESIGNATION AMENDMENT. If the maximum aggregate offering amount set forth in Recital B of the “Whereas” clause is not
raised within the time limits set forth in Section 1(b)(iii), the Buyers, and each of them, agree, upon the request of the Company, to an amendment of the Certificate of Designation to reduce the number of designated shares of Preferred Stock
to the number actually placed or such higher number as the Company may specify (not to exceed a number of shares of Preferred Stock with an aggregate Stated Value equal to the Maximum Amount) and to execute all resolutions, consents, agreements and
documents deemed necessary or advisable by the Company to evidence this reduction. 
 (w) SERIES A EXCHANGE. Holders of Series A
Preferred Stock may elect to exchange all or any portion (each, a “SERIES A EXCHANGE”) of their Series A Preferred Stock into Series B Preferred Stock in lieu of paying the Purchase Price in cash, provided that in order to effect a Series
A Exchange, a holder of Series A Preferred Stock must relinquish to the Company any and all warrants, options or other Common Stock Equivalents that it received in conjunction with its purchase of the amount of Series A Preferred Stock being
exchanged. Notwithstanding anything to the contrary herein, the amount of Series B Preferred Stock issued hereunder shall be limited such that, at the time of issuance of any Series B Preferred Stock, the aggregate Stated Value (not including
accrued and unpaid dividends) of the outstanding Series A Preferred Stock and the Series B Preferred Stock does not exceed $14,750,000. 
  

 36 








 5. SENIOR DEBT. The Company hereby represents that, except as otherwise set forth on SCHEDULE 5
annexed hereto there are no liens or encumbrances on the Company’s Property. The Company agrees that from the Issue Date of the Preferred Stock through the date that all of the Preferred Stock has been paid in full or converted in full (the
“Covered Period”), the Company shall not, and the Company shall not permit any of its Subsidiaries to, directly or indirectly, enter into, create, incur, assume or suffer to exist any mortgage, lien, pledge, charge, security interest or
other encumbrance (collectively, “Liens”) upon or in the Property (as defined below) owned by the Company or any of its Subsidiaries (except for capital leases, statutory tax liens and purchase money security interests) and shall not
assign or transfer any interest in the Patents owned by the Company or any of its Subsidiaries. In the event that the Company attempts to place any Lien or Liens on the Intellectual Property or attempts to assign or transfer any interest in the
Property during the Covered Period, the Buyer shall have the right to apply for an injunction in any state or federal courts sitting in the City of New York, borough of Manhattan to prevent such Lien or transfer. 
 For purposes hereof, “PROPERTY” shall mean any property of the Company, including but not limited to 
 (A) “Accounts”, “Cash Proceeds”, “Chattel Paper”, “Commercial Tort Claim”, “Commodity Account”,
“Commodity Contracts”, “Deposit Account”, “Documents”, “Equipment”, “Fixtures”, “General Intangibles”, “Goods”, “Instruments”, “Inventory”, “Investment
Property”, “Letter-of-Credit Rights”, “Noncash Proceeds”, “Payment Intangibles”, “Proceeds”, “Promissory Notes”, “Security”, “Record”, “Security Account”,
“Software”, and “Supporting Obligations,” as each such term is defined in the Uniform Commercial Code as in effect from time to time in the State of New York, 
 (B) real property, 
 (C) Intellectual Property
(as defined herein), and 
 (D) all other assets of the Company 
 6. LEGENDS. 
 (a) The Conversion Shares and the Warrant Shares, together with any other shares of
Common Stock that are issued or issuable pursuant to the Transaction Documents shall be referred to herein as the “ISSUED COMMON SHARES.” Certificates evidencing the Issued Common Shares shall not contain any legend restricting the
transfer thereof (including the legend set forth in Section 7(e) of the Certificate of Designation): (i) while a registration statement (including the Registration Statement) covering the resale of such security is effective under the
Securities Act, or (ii) following any sale of such Issued Common Shares pursuant to Rule 144, or (iii) if such Issued Common Shares are eligible for sale under Rule 144(k), or (iv) if such legend is not required under applicable
requirements of the Securities Act (including judicial interpretations and pronouncements issued by the staff of the Commission) (collectively, the “UNRESTRICTED CONDITIONS”). The Company shall cause its counsel to issue a legal opinion to
the Company’s transfer agent promptly after the Effective Date if required by the Company’s transfer agent to effect the issuance of Issued Common Shares without a restrictive 

  

 37 








 
legend or removal of the legend hereunder. If the Unrestricted Conditions are met at the time of issuance of Issued Common Shares, then such Issued Common
Shares shall be issued free of all legends. The Company agrees that following the Effective Date or at such time as the Unrestricted Conditions are met or such legend is otherwise no longer required under this Section 6(b), it will, no later
than three Trading Days following the delivery by a Buyer to the Company or the Company’s transfer agent of a certificate representing Issued Common Shares, as applicable, issued with a restrictive legend (such third Trading Day, the
“LEGEND REMOVAL DATE”), deliver or cause to be delivered to such Buyer a certificate representing such shares that is free from all restrictive and other legends. 
 (b) Each Buyer, severally and not jointly with the other Buyers, agrees that the removal of the restrictive legend from certificates representing
Securities as set forth in this Section 6 is predicated upon the Company’s reliance that each Buyer will sell any Securities pursuant to either the registration requirements of the Securities Act, including any applicable prospectus
delivery requirements, or an exemption therefrom, and that if Securities are sold pursuant to a Registration Statement, they will be sold in compliance with the plan of distribution set forth therein. 
 7. CONDITIONS TO THE COMPANY’S OBLIGATION TO SELL. The obligation of the Company hereunder to issue and sell the Preferred Stock and Warrants
to a Buyer at the Closing is subject to the satisfaction, at or before the Closing Date, of each of the following conditions thereto, provided that these conditions are for the Company’s sole benefit and may be waived by the Company at any time
in its sole discretion: 
 (a) The Buyer shall have executed each of the Transaction Documents that requires its signature, and delivered the
same to the Company. 
 (b) The Buyer shall have delivered the applicable Purchase Price in accordance with Section 1(b) above, provided
that the Lead Investor (as defined in Section 4(q)) may withhold its Lead Investor Fee (as defined in Section 4(q) from its Purchase Price and deliver the net amount to the Company. 
 (c) The representations and warranties of the Buyer shall be true and correct in all material respects as of the date when made and as of the applicable
Closing Date as though made at that time (except for representations and warranties that speak as of a specific date, which representations and warranties shall be true and correct as of such date), and the Buyer shall have performed, satisfied and
complied in all material respects with the covenants, agreements and conditions required by this Agreement to be performed, satisfied or complied with by the Buyer at or prior to the Closing Date. 
 (d) No litigation, statute, rule, regulation, executive order, decree, ruling or injunction shall have been enacted, entered, promulgated or endorsed by
or in any court or governmental authority of competent jurisdiction or any self-regulatory organization having authority over the matters contemplated hereby which prohibits the consummation of any of the transactions contemplated by this Agreement.

  

 38 








 8. CONDITIONS TO BUYER’S OBLIGATION TO PURCHASE. The obligation of each Buyer hereunder to
purchase the Preferred Stock and Warrants at each Closing is subject to the satisfaction, at or before the Closing Date, of each of the following conditions, provided that these conditions are for such Buyer’s sole benefit and may be waived by
such Buyer at any time in its sole discretion: 
 (a) The Company shall have executed this Agreement and the Registration Rights Agreement,
and delivered the same to the Buyer. 
 (b) The Company shall have delivered to such Buyer the duly executed Certificate of Designation and
Warrants in accordance with Section 1 above. 
 (c) The representations and warranties of the Company contained in this Agreement, as
modified by the Exhibits and Schedules hereto, shall be true and correct in all material respects as of the date when made and as of the Closing Date as though made at such time (except for representations and warranties that speak as of a specific
date, which representations and warranties shall be true and correct as of such date) and the Company shall have performed, satisfied and complied in all material respects with the covenants, agreements and conditions required by this Agreement to
be performed, satisfied or complied with by the Company at or prior to the Closing Date. The Buyer shall have received a certificate or certificates, executed by the President and Chief Executive Officer of the Company, dated as of the applicable
Closing Date, to the foregoing effect and as to such other matters as may be reasonably requested by such Buyer including, but not limited to certificates with respect to the Company’s Certificate of Incorporation, By-laws and Board of
Directors’ resolutions relating to the transactions contemplated hereby. 
 (d) No litigation, statute, rule, regulation, executive
order, decree, ruling or injunction shall have been enacted, entered, promulgated or endorsed by or in any court or governmental authority of competent jurisdiction or any self-regulatory organization having authority over the matters contemplated
hereby which prohibits the consummation of any of the transactions contemplated by this Agreement. 
 (e) Trading in the Common Stock on the
PRINCIPAL MARKET shall not have been suspended by the SEC or the Nasdaq, if applicable, and, within two (2) business days of the Closing, the Company will make application to the PRINCIPAL MARKET, if legally required by Nasdaq, to have the
Conversion Shares and the Warrant Shares authorized for quotation. 
 (f) The Buyer shall have received an opinion of the Company’s
counsel, dated as of the Closing Date, in form, scope and substance reasonably satisfactory to the Buyer and in substantially the same form as EXHIBIT E attached hereto. 
 (g) The Buyer shall have received a Closing Certificate described in Section 1(b)(v) above, dated as of the Closing Date. 
 (h) The Company shall have delivered to the Buyer an executed Accountant Letter and an executed Law Firm Letter, as described in Section 3(dd)
hereof. 
  

 39 








 (i) The Company shall have received funds from Buyers representing their respective Purchase Prices in an
amount equal to or exceeding the Minimum Amount, in the aggregate, and not exceeding the Maximum Amount, in the aggregate. 
 (j) No Material
Adverse Changes have occurred since the date that the Buyer executed this Agreement. 
 9. GOVERNING LAW; MISCELLANEOUS. 

(a) GOVERNING LAW. All questions concerning the construction, validity, enforcement and interpretation of this Agreement and the other
Transaction Documents shall be governed by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles of conflicts of law thereof. Each party agrees that all legal proceedings
concerning the interpretations, enforcement and defense of the transactions contemplated by this Agreement and any other Transaction Documents (whether brought against a party hereto or its respective affiliates, directors, officers, stockholders,
employees or agents) shall be commenced exclusively in the state and federal courts sitting in the City of New York. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in the City of New York,
borough of Manhattan for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein (including with respect to the enforcement of any of the Transaction Documents), and hereby
irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is improper or is an inconvenient venue for such
proceeding. Each party hereby irrevocably waives personal service of process and consents to process being served in any such suit, action or proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence
of delivery) to such party at the address in effect for notices to it under this Agreement and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in
any way any right to serve process in any other manner permitted by law. The parties hereby waive all rights to a trial by jury. If either party shall commence an action or proceeding to enforce any provisions of the Transaction Documents, then the
prevailing party in such action or proceeding shall be reimbursed by the other party for its reasonable attorneys’ fees and other costs and expenses incurred with the investigation, preparation and prosecution of such action or proceeding.

 (b) COUNTERPARTS; SIGNATURES BY FACSIMILE. This Agreement may be executed in one or more counterparts, all of which shall be
considered one and the same agreement and shall become effective when counterparts have been signed by each party and delivered to the other party. This Agreement, once executed by a party, may be delivered to the other party hereto by facsimile
transmission of a copy of this Agreement bearing the signature of the party so delivering this Agreement. 
 (c) HEADINGS. The
headings of this Agreement are for convenience of reference and shall not form part of, or affect the interpretation of, this Agreement. 
  

 40 








 (d) SEVERABILITY. If any provision of this Agreement shall be invalid or unenforceable in any
jurisdiction, such invalidity or unenforceability shall not affect the validity or enforceability of the remainder of this Agreement or the validity or enforceability of this Agreement in any other jurisdiction. 
 (e) ENTIRE AGREEMENT; AMENDMENTS. This Agreement and the instruments referenced herein contain the entire understanding of the parties with
respect to the matters covered herein and therein and supersede all previous communication, representation, or Agreements whether oral or written, between the parties with respect to the matters covered herein. Except as specifically set forth
herein or therein, neither the Company nor the Buyer makes any representation, warranty, covenant or undertaking with respect to such matters. The Agreement may not be orally modified. Only a modification in writing, signed authorized
representatives of both parties will be enforceable. The parties waive the right to rely on any oral representations made by the other party, whether in the past or in the future, regarding the subject matter of the Agreement, the instruments
referenced herein or any other dealings between the parties related to investments or potential investments into the Company or any securities transactions or potential securities transactions with the Company. 
 (f) INDEPENDENT NATURE OF BUYERS’ OBLIGATIONS AND RIGHTS. The obligations of each Buyer under any Transaction Document are several and not
joint with the obligations of any other Buyer, and no Buyer shall be responsible in any way for the performance of the obligations of any other Buyer under any Transaction Document. Nothing contained herein or in any Transaction Document, and no
action taken by any Buyer pursuant thereto, shall be deemed to constitute the Buyers as a partnership, an association, a joint venture or any other kind of entity, or create a presumption that the Buyers are in any way acting in concert or as a
group with respect to such obligations or the transactions contemplated by the Transaction Documents. Each Buyer shall be entitled to independently protect and enforce its rights, including without limitation, the rights arising out of this
Agreement or out of the other Transaction Documents, and it shall not be necessary for any other Buyer to be joined as an additional party in any proceeding for such purpose. Each Buyer has been represented by its own separate legal counsel in its
review and negotiation of the Transaction Documents. 
 (g) NOTICES. Any notices required or permitted to be given under the terms of
this Agreement shall be sent by certified or registered mail (return receipt requested) or delivered personally or by courier (including a recognized overnight delivery service) or by facsimile and shall be effective five days after being placed in
the mail, if mailed by regular United States mail, or upon receipt, if delivered personally or by courier (including a recognized overnight delivery service) or by facsimile, in each case addressed to a party. The addresses for such communications
shall be: 
  

 41 








 If to the Company, to: 
 Attn: Belinda Tsao Nivaggioli, Chief Executive Officer 
 Avicena Group, Inc. 
 228 Hamilton Avenue; 3rd floor 
 Palo Alto,
CA 94301 

			
	Phone:	 	415-397-2880
	Fax:	 	415-397-2898

 With copy to: 
  

					
		  	After May 25, 2007, address changes to:
	Lance R. Rodgers, Esq.	  		  	
	 Barack Ferrazzano Kirschbaum Perlman &
 Nagelberg LLP
	  		  	
	333 West Wacker Drive, Suite 2700	  	200 West Madison Street, Suite 3900	  	
	Chicago, Illinois 60606	  	Chicago, IL 60606	  	
	Phone: (312) 984-3100	  		  	
	Fax: (312) 984-3150	  		  	

 If to a Buyer: To the address set forth immediately below such Buyer’s name on the signature
pages hereto. 
 Each party shall provide notice to the other party of any change in address. 
 (h) SUCCESSORS AND ASSIGNS. This Agreement shall be binding upon and inure to the benefit of the parties and their successors and assigns. Neither
the Company nor any Buyer shall assign this Agreement or any rights or obligations hereunder without the prior written consent of the other. Notwithstanding the foregoing, subject to Section 2(f), Buyer may assign its rights hereunder to any
person that purchases Securities in a private transaction from a Buyer or to any of its “AFFILIATES,” as that term is defined under the 1934 Act, without the consent of the Company; PROVIDED, HOWEVER, that prior to any assignment of its
rights hereunder to a person (other than an assignment to an affiliate of the Buyer or an assignment to a liquidation account of Buyer or similar internal assignment, if Buyer is an investment fund) that purchases any Preferred Stock or Warrants
from such Buyer in a private transaction such Buyer shall provide the Company with written notice of its intention to sell some or all of the Preferred Stock or Warrants, which notice shall disclose the proposed purchase price for such Preferred
Stock or Warrants, and the Company shall have the option, during the ten (10) business day period following such notice, to purchase all, but not less than all, of such Preferred Stock and/or Warrants at the proposed purchase price, after which
period the Buyer shall be free to sell the Preferred Stock and/or Warrants to a third party at such proposed purchase price. 
 (i) THIRD
PARTY BENEFICIARIES. This Agreement is intended for the benefit of the parties hereto and their respective permitted successors and assigns, and is not for the benefit of, nor may any provision hereof be enforced by, any other person.

  

 42 








 (j) SURVIVAL. The representations and warranties of the parties hereto contained in this Agreement
shall survive the closing hereunder for the maximum period permitted by law notwithstanding any due diligence investigation conducted by or on behalf of the Buyer. 
 (k) INDEMNIFICATION. The Company (the “INDEMNIFYING PARTY”) agrees to indemnify and hold harmless the Buyer and all its officers, directors, employees, agents, members and managers (the
“INDEMNIFIED PARTY”) for loss or damage arising as a result of or related to any breach or alleged breach by the Company of any of its representations, warranties and covenants set forth in Sections 3 and 4 hereof or any of its covenants
and obligations under this Agreement or the Registration Rights Agreement, including advancement of expenses as they are incurred with respect to claims by third parties. 
 Promptly after receipt of notice of the commencement of any action against an Indemnified Party, such Indemnified Party shall notify the Indemnifying
Party in writing of the commencement thereof and the basis hereunder upon which a claim for indemnification is asserted, but the failure to do so shall not relieve the Indemnifying Party of its obligations hereunder except to the extent the
Indemnifying Party is materially prejudiced by such failure. In the event of the commencement of any such action, the Indemnifying Party shall be entitled to participate therein and to assume the defense thereof with counsel satisfactory to the
Indemnified Party, and, after notice from the Indemnifying Party to the Indemnified Party of its election so to assume the defense thereof, the Indemnifying Party shall not be liable to the Indemnified Party hereunder for any legal expenses
(including attorneys’ fees) subsequently incurred by such Indemnified Party in connection with the defense thereof other than reasonable costs of investigation and of liaison with counsel so selected, PROVIDED, HOWEVER, that, if the defendants
in any such action include both the Indemnified Party and the Indemnifying Party and the Indemnified Party shall have reasonably concluded that there may be reasonable defenses available to it which are different from or additional to those
available to the Indemnifying Party or if the interests of the Indemnified Party reasonably may be deemed to conflict with the interests of the Indemnifying Party, the Indemnified Party shall have the right to select one separate counsel and to
assume such legal defenses and otherwise to participate in the defense of such action, with the reasonable expenses and fees of such separate counsel and other expenses related to such participation to be reimbursed by the Indemnifying Party as
incurred. 
 As to cases in which the Indemnifying Party has assumed and is providing the defense for the Indemnified Party, the control of
such defense shall be vested in the Indemnifying Party; provided that the consent of the Indemnified Party shall be required prior to any settlement of such case or action, which consent shall not be unreasonably withheld. As to any action, the
party which is controlling such action shall provide to the other party reasonable information (including reasonable advance notice of all proceedings and depositions in respect thereto) regarding the conduct of the action and the right to attend
all proceedings and depositions in respect thereto through its agents and attorneys, and the right to discuss the action with counsel for the party controlling such action. 
 (l) PUBLICITY. The Company and the Buyer shall have the right to review a reasonable period of time before issuance of any press releases, filings
with the SEC, NASD or any stock exchange or interdealer quotation system, or any other public statements with respect to the transactions contemplated hereby; PROVIDED, HOWEVER, that the Company shall be 

  

 43 








 
entitled, without the prior approval of the Buyer, to make any press release or public filings with respect to such transactions as is required by applicable
law and regulations (although the Buyer shall be consulted by the Company in connection with any such press release prior to its release and shall be provided with a copy thereof and be given an opportunity to comment thereon). 
 (m) FURTHER ASSURANCES. Each party shall do and perform, or cause to be done and performed, all such further acts and things, and shall execute
and deliver all such other agreements, certificates, instruments and documents, as the other party may reasonably request in order to carry out the intent and accomplish the purposes of this Agreement and the consummation of the transactions
contemplated hereby. 
 (n) NO STRICT CONSTRUCTION. The language used in this Agreement will be deemed to be the language chosen by
the parties to express their mutual intent, and no rules of strict construction will be applied against any party. 
 (o) LIQUIDATED
DAMAGES. The Company’s obligations to pay any partial liquidated damages or other amounts owing under the Transaction Documents is a continuing obligation of the Company and shall not terminate until all unpaid partial liquidated damages
and other amounts have been paid notwithstanding the fact that the instrument or security pursuant to which such partial liquidated damages or other amounts are due and payable shall have been canceled. 
 (p) REMEDIES. The Company acknowledges that a breach by it of its obligations hereunder will cause irreparable harm to Buyer, by vitiating the
intent and purpose of the transactions contemplated hereby. Accordingly, the Company acknowledges that the remedy at law for a breach of its obligations under this Agreement will be inadequate and agrees, in the event of a breach or threatened
breach by the Company of the provisions of this Agreement, that Buyer shall be entitled, in addition to all other available remedies in law or in equity, to an injunction or injunctions to prevent or cure any breaches of the provisions of this
Agreement and to enforce specifically the terms and provisions of this Agreement, without the necessity of showing economic loss and without any bond or other security being required. 
 10. NUMBER OF SHARES AND PURCHASE PRICE. Buyer subscribes for Series B Preferred Stock having an aggregate Stated Value equal to the
subscription amount (“SUBSCRIPTION AMOUNT”) set forth on such Buyer’s signature page below against payment by wire transfer in the amount of the Subscription Amount (less any offset of expenses as permitted hereunder). 
 The undersigned acknowledges that this Agreement and the subscription represented hereby shall not be effective unless accepted by the Company as
indicated below. 
 [INTENTIONALLY LEFT BLANK] 
  


 44 








 IN WITNESS WHEREOF, the undersigned Buyer does represent and certify under penalty of perjury that the
foregoing statements are true and correct and that Buyer by the following signature(s) executed this Agreement. 
 Dated this 30th day of March, 2007.

  

							
	 /s/ Eric S. Swartz
	 		 	 BridgePointe Master Fund Ltd.

	Your Signature	 		 	PRINT EXACT NAME IN WHICH YOU WANT THE SECURITIES TO BE REGISTERED

 Buyer’s Subscription Amout: $2,000,000. 
 Buyer’s Entity Type and Residency: Cayman Islands Exempted Company. 
  

							
	 Eric S. Swartz
	 		 	DELIVERY INSTRUCTIONS:
	Name: Please Print	 		 	Please type or print address where your security is to be delivered
				
	 Director
	 		 	ATTN.:	 	 P. Bradford Hathorn, Esq.



							
	Title/Representative Capacity (if applicable)	 		 		 	
			
	  
	 		 	 1125 Sanctuary Parkway, Ste 275

	Name of Company You Represent (if applicable)	 		 	Street Address	 	
			
	  
	 		 	 Alpharetta, GA 30004

	Place of Execution of this Agreement	 		 	City, State or Province, Country, Offshore Postal Code

  

			
	 770-640-8130
	 	
	Phone Number (For Federal Express) and Fax Number (re: Notice)

 WITH A COPY TO: 
 Please type or print address where copies are to be delivered 
  

			
	ATTN.:	 	 N/A



	
	
	  

	Street Address
	
	  

	City, State or Province, Country, Offshore Postal Code
	
	  

	Phone Number (For Federal Express) and Fax Number (re: Notice)

 THIS AGREEMENT IS ACCEPTED BY THE COMPANY IN THE AMOUNT OF $ 2,000,000 (“SUBSCRIPTION AMOUNT”) ON
THE 30th DAY OF MARCH, 2007. 
  

			
	AVICENA GROUP, INC.
		
	By:	 	 /s/ Belinda Tsao Nivaggioli

		 	Belinda Tsao Nivaggioli, Chief Executive Officer


  

 45 








 SCHEDULE 1(A) 
 TO SECURITIES PURHASE AGREEMENT 
 OF AVICENA GROUP, INC. 
  

											
	 	  	Yr.1	  	Yr.2	  	Yr.3	  	Yr.4	  	Yr.5
	 $4.50-$6.99
	  	2M	  	2M	  	1.5	  	1.5	  	1.5
	 $4.00-$4.49
	  	1M	  	1M	  	1M	  	1M	  	1M
	 $3.50-$3.99
	  	500K	  	500K	  	500K	  	500K	  	500K
	 Total
	  	3.5M	  	3.5M	  	3.0M	  	3.0M	  	3.0M

 The numbers in each cell of the above matrix represent the maximum number of options to employees,
officers, directors, consultants and advisors (and any individuals who have accepted an offer of employment) that will be considered to be “Exempt Issuances,” when issued in the respective specified years, and at the respective specified
prices. For purposes hereof 
 – “Year 1” means the period from the Closing Date to the first anniversary of the Closing Date,

 – “Year 2” means the period from the end of Year 1 to the second anniversary of the Closing Date, 
 – “Year 3” means the period from the end of Year 2 to the third anniversary of the Closing Date, 
 – “Year 4” means the period from the end of Year 3 to the fourth anniversary of the Closing Date, 
 – “Year 5” means the period from the end of Year 4 to the fifth anniversary of the Closing Date. 
 The prices specified on the left side of the matrix represent the range of exercise prices at which the specified number of options may be issued in the
specified year, in order to be considered “Exempt Issuances”. In addition to the foregoing, any grants of options (to employees, officers, directors, consultants and advisors and any individuals who have accepted an offer of employment, in
each case in connection with any Approved Stock Plan), to purchase shares of Common Stock at exercise prices of $7.00 or above, will be considered “Exempt Issuances.” 
  

 46